Form 6-K NOVO NORDISK A S For: Dec 31

February 3, 2021 2:04 PM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
nvo-20201231
00003532786-K31/12/20202020FY12/31false44733624900003532782020-01-012020-12-31iso4217:DKK00003532782019-01-012019-12-3100003532782018-01-012018-12-31iso4217:DKKxbrli:shares00003532782019-12-3100003532782018-12-3100003532782017-12-3100003532782020-12-310000353278ifrs-full:IssuedCapitalMember2019-12-310000353278ifrs-full:TreasurySharesMember2019-12-310000353278ifrs-full:RetainedEarningsMember2019-12-310000353278ifrs-full:OtherReservesMember2019-12-310000353278ifrs-full:IssuedCapitalMember2018-12-310000353278ifrs-full:TreasurySharesMember2018-12-310000353278ifrs-full:RetainedEarningsMember2018-12-310000353278ifrs-full:OtherReservesMember2018-12-310000353278ifrs-full:IssuedCapitalMember2017-12-310000353278ifrs-full:TreasurySharesMember2017-12-310000353278ifrs-full:RetainedEarningsMember2017-12-310000353278ifrs-full:OtherReservesMember2017-12-310000353278ifrs-full:RetainedEarningsMember2020-01-012020-12-310000353278ifrs-full:RetainedEarningsMember2019-01-012019-12-310000353278ifrs-full:RetainedEarningsMember2018-01-012018-12-310000353278ifrs-full:OtherReservesMember2020-01-012020-12-310000353278ifrs-full:OtherReservesMember2019-01-012019-12-310000353278ifrs-full:OtherReservesMember2018-01-012018-12-310000353278ifrs-full:TreasurySharesMember2020-01-012020-12-310000353278ifrs-full:TreasurySharesMember2019-01-012019-12-310000353278ifrs-full:TreasurySharesMember2018-01-012018-12-310000353278ifrs-full:IssuedCapitalMember2020-01-012020-12-310000353278ifrs-full:IssuedCapitalMember2019-01-012019-12-310000353278ifrs-full:IssuedCapitalMember2018-01-012018-12-310000353278ifrs-full:IssuedCapitalMember2020-12-310000353278ifrs-full:TreasurySharesMember2020-12-310000353278ifrs-full:RetainedEarningsMember2020-12-310000353278ifrs-full:OtherReservesMember2020-12-310000353278nvo:IFRS16Member2019-01-010000353278nvo:USManagedCareAndMedicareMembercountry:US2020-01-012020-12-310000353278nvo:USManagedCareAndMedicareMembercountry:US2019-01-012019-12-310000353278nvo:USManagedCareAndMedicareMembercountry:US2018-01-012018-12-310000353278country:USnvo:USWholesalerMember2020-01-012020-12-310000353278country:USnvo:USWholesalerMember2019-01-012019-12-310000353278country:USnvo:USWholesalerMember2018-01-012018-12-310000353278nvo:USMedicaidMembercountry:US2020-01-012020-12-310000353278nvo:USMedicaidMembercountry:US2019-01-012019-12-310000353278nvo:USMedicaidMembercountry:US2018-01-012018-12-310000353278nvo:OtherCustomersMembercountry:US2020-01-012020-12-310000353278nvo:OtherCustomersMembercountry:US2019-01-012019-12-310000353278nvo:OtherCustomersMembercountry:US2018-01-012018-12-310000353278nvo:OtherCustomersMembernvo:NonNorthAmericaMember2020-01-012020-12-310000353278nvo:OtherCustomersMembernvo:NonNorthAmericaMember2019-01-012019-12-310000353278nvo:OtherCustomersMembernvo:NonNorthAmericaMember2018-01-012018-12-310000353278nvo:RebatesProvisionMember2019-12-310000353278nvo:RebatesProvisionMember2018-12-310000353278nvo:RebatesProvisionMember2017-12-310000353278nvo:RebatesProvisionMember2020-01-012020-12-310000353278nvo:RebatesProvisionMember2019-01-012019-12-310000353278nvo:RebatesProvisionMember2018-01-012018-12-310000353278nvo:RebatesProvisionMember2020-12-31xbrli:pure0000353278srt:NorthAmericaMember2020-01-012020-12-310000353278srt:NorthAmericaMember2019-01-012019-12-310000353278srt:NorthAmericaMember2018-01-012018-12-310000353278ifrs-full:NongovernmentCustomersMembercountry:USnvo:USWholesalerMember2020-01-012020-12-310000353278ifrs-full:GovernmentCustomersMembernvo:USMedicaidMembercountry:US2020-01-012020-12-31nvo:wholesaler0000353278nvo:WholesalerOneMember2020-01-012020-12-310000353278nvo:WholesalerTwoMember2020-01-012020-12-310000353278nvo:WholesalerThreeMember2020-01-012020-12-310000353278nvo:WholesalerOneMember2019-01-012019-12-310000353278nvo:WholesalerTwoMember2019-01-012019-12-310000353278nvo:WholesalerThreeMember2019-01-012019-12-310000353278nvo:WholesalerOneMember2018-01-012018-12-310000353278nvo:WholesalerTwoMember2018-01-012018-12-310000353278nvo:WholesalerThreeMember2018-01-012018-12-310000353278ifrs-full:OperatingSegmentsMembernvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278ifrs-full:OperatingSegmentsMembernvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278ifrs-full:OperatingSegmentsMembernvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278ifrs-full:OperatingSegmentsMembernvo:BiopharmMember2020-01-012020-12-310000353278ifrs-full:OperatingSegmentsMembernvo:BiopharmMember2019-01-012019-12-310000353278ifrs-full:OperatingSegmentsMembernvo:BiopharmMember2018-01-012018-12-31nvo:segment0000353278nvo:UnitedStatesAndChinaMember2020-01-012020-12-31nvo:commercial_unit0000353278ifrs-full:ForeignCountriesMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:LongActingInsulinMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:LongActingInsulinMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:LongActingInsulinMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:LongActingInsulinMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:LongActingInsulinMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:LongActingInsulinMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:LongActingInsulinMembercountry:CN2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:LongActingInsulinMembercountry:CN2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:LongActingInsulinMembercountry:CN2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:LongActingInsulinMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:LongActingInsulinMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:LongActingInsulinMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembersrt:NorthAmericaMembernvo:LongActingInsulinMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembersrt:NorthAmericaMembernvo:LongActingInsulinMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembersrt:NorthAmericaMembernvo:LongActingInsulinMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembercountry:USnvo:LongActingInsulinMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembercountry:USnvo:LongActingInsulinMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembercountry:USnvo:LongActingInsulinMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:LongActingInsulinMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:LongActingInsulinMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:LongActingInsulinMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:TresibaMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:TresibaMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:TresibaMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TresibaMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TresibaMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TresibaMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TresibaMembercountry:CN2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TresibaMembercountry:CN2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TresibaMembercountry:CN2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TresibaMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TresibaMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TresibaMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TresibaMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TresibaMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TresibaMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TresibaMembercountry:US2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TresibaMembercountry:US2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TresibaMembercountry:US2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TresibaMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TresibaMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TresibaMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:XultophyMembernvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:XultophyMembernvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:XultophyMembernvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278nvo:XultophyMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:XultophyMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:XultophyMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:XultophyMembernvo:DiabetesAndObesityCareMembercountry:CN2020-01-012020-12-310000353278nvo:XultophyMembernvo:DiabetesAndObesityCareMembercountry:CN2019-01-012019-12-310000353278nvo:XultophyMembernvo:DiabetesAndObesityCareMembercountry:CN2018-01-012018-12-310000353278nvo:XultophyMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:XultophyMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:XultophyMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:XultophyMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:XultophyMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:XultophyMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:XultophyMembernvo:DiabetesAndObesityCareMembercountry:US2020-01-012020-12-310000353278nvo:XultophyMembernvo:DiabetesAndObesityCareMembercountry:US2019-01-012019-12-310000353278nvo:XultophyMembernvo:DiabetesAndObesityCareMembercountry:US2018-01-012018-12-310000353278nvo:XultophyMembernvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278nvo:XultophyMembernvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278nvo:XultophyMembernvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:LevemirMembernvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:LevemirMembernvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:LevemirMembernvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278nvo:LevemirMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:LevemirMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:LevemirMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:LevemirMembernvo:DiabetesAndObesityCareMembercountry:CN2020-01-012020-12-310000353278nvo:LevemirMembernvo:DiabetesAndObesityCareMembercountry:CN2019-01-012019-12-310000353278nvo:LevemirMembernvo:DiabetesAndObesityCareMembercountry:CN2018-01-012018-12-310000353278nvo:LevemirMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:LevemirMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:LevemirMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:LevemirMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:LevemirMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:LevemirMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:LevemirMembernvo:DiabetesAndObesityCareMembercountry:US2020-01-012020-12-310000353278nvo:LevemirMembernvo:DiabetesAndObesityCareMembercountry:US2019-01-012019-12-310000353278nvo:LevemirMembernvo:DiabetesAndObesityCareMembercountry:US2018-01-012018-12-310000353278nvo:LevemirMembernvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278nvo:LevemirMembernvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278nvo:LevemirMembernvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:PremixInsulinMembernvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:PremixInsulinMembernvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:PremixInsulinMembernvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278nvo:PremixInsulinMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:PremixInsulinMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:PremixInsulinMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:PremixInsulinMembernvo:DiabetesAndObesityCareMembercountry:CN2020-01-012020-12-310000353278nvo:PremixInsulinMembernvo:DiabetesAndObesityCareMembercountry:CN2019-01-012019-12-310000353278nvo:PremixInsulinMembernvo:DiabetesAndObesityCareMembercountry:CN2018-01-012018-12-310000353278nvo:PremixInsulinMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:PremixInsulinMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:PremixInsulinMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:PremixInsulinMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:PremixInsulinMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:PremixInsulinMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:PremixInsulinMembernvo:DiabetesAndObesityCareMembercountry:US2020-01-012020-12-310000353278nvo:PremixInsulinMembernvo:DiabetesAndObesityCareMembercountry:US2019-01-012019-12-310000353278nvo:PremixInsulinMembernvo:DiabetesAndObesityCareMembercountry:US2018-01-012018-12-310000353278nvo:PremixInsulinMembernvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278nvo:PremixInsulinMembernvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278nvo:PremixInsulinMembernvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:RyzodegMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:RyzodegMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:RyzodegMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RyzodegMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RyzodegMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RyzodegMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RyzodegMembercountry:CN2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RyzodegMembercountry:CN2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RyzodegMembercountry:CN2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RyzodegMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RyzodegMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RyzodegMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RyzodegMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RyzodegMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RyzodegMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RyzodegMembercountry:US2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RyzodegMembercountry:US2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RyzodegMembercountry:US2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RyzodegMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RyzodegMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RyzodegMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278nvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMembercountry:CN2020-01-012020-12-310000353278nvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMembercountry:CN2019-01-012019-12-310000353278nvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMembercountry:CN2018-01-012018-12-310000353278nvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMembercountry:US2020-01-012020-12-310000353278nvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMembercountry:US2019-01-012019-12-310000353278nvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMembercountry:US2018-01-012018-12-310000353278nvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278nvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278nvo:NovoMixAndNovoLogMixMembernvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:FastActingInsulinMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:FastActingInsulinMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:FastActingInsulinMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:FastActingInsulinMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:FastActingInsulinMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:FastActingInsulinMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:FastActingInsulinMembercountry:CN2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:FastActingInsulinMembercountry:CN2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:FastActingInsulinMembercountry:CN2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:FastActingInsulinMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:FastActingInsulinMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:FastActingInsulinMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembersrt:NorthAmericaMembernvo:FastActingInsulinMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembersrt:NorthAmericaMembernvo:FastActingInsulinMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembersrt:NorthAmericaMembernvo:FastActingInsulinMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembercountry:USnvo:FastActingInsulinMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembercountry:USnvo:FastActingInsulinMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembercountry:USnvo:FastActingInsulinMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:FastActingInsulinMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:FastActingInsulinMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:FastActingInsulinMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:FiaspMembernvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:FiaspMembernvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:FiaspMembernvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278nvo:FiaspMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:FiaspMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:FiaspMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:FiaspMembernvo:DiabetesAndObesityCareMembercountry:CN2020-01-012020-12-310000353278nvo:FiaspMembernvo:DiabetesAndObesityCareMembercountry:CN2019-01-012019-12-310000353278nvo:FiaspMembernvo:DiabetesAndObesityCareMembercountry:CN2018-01-012018-12-310000353278nvo:FiaspMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:FiaspMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:FiaspMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:FiaspMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:FiaspMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:FiaspMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:FiaspMembernvo:DiabetesAndObesityCareMembercountry:US2020-01-012020-12-310000353278nvo:FiaspMembernvo:DiabetesAndObesityCareMembercountry:US2019-01-012019-12-310000353278nvo:FiaspMembernvo:DiabetesAndObesityCareMembercountry:US2018-01-012018-12-310000353278nvo:FiaspMembernvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278nvo:FiaspMembernvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278nvo:FiaspMembernvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:NovoRapidAndNovoLogMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:NovoRapidAndNovoLogMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:NovoRapidAndNovoLogMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:EMEAMembernvo:NovoRapidAndNovoLogMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:EMEAMembernvo:NovoRapidAndNovoLogMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:EMEAMembernvo:NovoRapidAndNovoLogMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembercountry:CNnvo:NovoRapidAndNovoLogMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembercountry:CNnvo:NovoRapidAndNovoLogMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembercountry:CNnvo:NovoRapidAndNovoLogMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:NovoRapidAndNovoLogMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:NovoRapidAndNovoLogMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:NovoRapidAndNovoLogMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembersrt:NorthAmericaMembernvo:NovoRapidAndNovoLogMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembersrt:NorthAmericaMembernvo:NovoRapidAndNovoLogMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembersrt:NorthAmericaMembernvo:NovoRapidAndNovoLogMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembercountry:USnvo:NovoRapidAndNovoLogMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembercountry:USnvo:NovoRapidAndNovoLogMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembercountry:USnvo:NovoRapidAndNovoLogMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:NovoRapidAndNovoLogMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:NovoRapidAndNovoLogMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:NovoRapidAndNovoLogMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:HumanInsulinMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:HumanInsulinMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:HumanInsulinMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:HumanInsulinMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:HumanInsulinMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:HumanInsulinMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:HumanInsulinMembercountry:CN2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:HumanInsulinMembercountry:CN2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:HumanInsulinMembercountry:CN2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:HumanInsulinMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:HumanInsulinMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:HumanInsulinMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:HumanInsulinMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:HumanInsulinMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:HumanInsulinMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:HumanInsulinMembercountry:US2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:HumanInsulinMembercountry:US2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:HumanInsulinMembercountry:US2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:HumanInsulinMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:HumanInsulinMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:HumanInsulinMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:TotalInsulinMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:TotalInsulinMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:TotalInsulinMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalInsulinMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalInsulinMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalInsulinMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalInsulinMembercountry:CN2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalInsulinMembercountry:CN2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalInsulinMembercountry:CN2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalInsulinMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalInsulinMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalInsulinMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalInsulinMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalInsulinMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalInsulinMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalInsulinMembercountry:US2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalInsulinMembercountry:US2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalInsulinMembercountry:US2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalInsulinMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalInsulinMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalInsulinMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:VictozaMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:VictozaMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:VictozaMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:VictozaMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:VictozaMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:VictozaMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:VictozaMembercountry:CN2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:VictozaMembercountry:CN2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:VictozaMembercountry:CN2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:VictozaMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:VictozaMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:VictozaMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:VictozaMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:VictozaMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:VictozaMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:VictozaMembercountry:US2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:VictozaMembercountry:US2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:VictozaMembercountry:US2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:VictozaMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:VictozaMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:VictozaMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:OzempicMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:OzempicMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:OzempicMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OzempicMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OzempicMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OzempicMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OzempicMembercountry:CN2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OzempicMembercountry:CN2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OzempicMembercountry:CN2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OzempicMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OzempicMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OzempicMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OzempicMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OzempicMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OzempicMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OzempicMembercountry:US2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OzempicMembercountry:US2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OzempicMembercountry:US2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OzempicMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OzempicMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OzempicMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:RybelsusMembernvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:RybelsusMembernvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:RybelsusMembernvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278nvo:RybelsusMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:RybelsusMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:RybelsusMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:RybelsusMembernvo:DiabetesAndObesityCareMembercountry:CN2020-01-012020-12-310000353278nvo:RybelsusMembernvo:DiabetesAndObesityCareMembercountry:CN2019-01-012019-12-310000353278nvo:RybelsusMembernvo:DiabetesAndObesityCareMembercountry:CN2018-01-012018-12-310000353278nvo:RybelsusMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:RybelsusMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:RybelsusMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:RybelsusMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:RybelsusMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:RybelsusMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:RybelsusMembernvo:DiabetesAndObesityCareMembercountry:US2020-01-012020-12-310000353278nvo:RybelsusMembernvo:DiabetesAndObesityCareMembercountry:US2019-01-012019-12-310000353278nvo:RybelsusMembernvo:DiabetesAndObesityCareMembercountry:US2018-01-012018-12-310000353278nvo:RybelsusMembernvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278nvo:RybelsusMembernvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278nvo:RybelsusMembernvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:TotalGLP1Member2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:TotalGLP1Member2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:TotalGLP1Member2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:EMEAMembernvo:TotalGLP1Member2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:EMEAMembernvo:TotalGLP1Member2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:EMEAMembernvo:TotalGLP1Member2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembercountry:CNnvo:TotalGLP1Member2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembercountry:CNnvo:TotalGLP1Member2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembercountry:CNnvo:TotalGLP1Member2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalGLP1Membernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalGLP1Membernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalGLP1Membernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembersrt:NorthAmericaMembernvo:TotalGLP1Member2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembersrt:NorthAmericaMembernvo:TotalGLP1Member2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembersrt:NorthAmericaMembernvo:TotalGLP1Member2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembercountry:USnvo:TotalGLP1Member2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembercountry:USnvo:TotalGLP1Member2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembercountry:USnvo:TotalGLP1Member2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalGLP1Member2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalGLP1Member2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:TotalGLP1Member2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMembercountry:CN2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMembercountry:CN2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMembercountry:CN2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMembercountry:US2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMembercountry:US2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMembercountry:US2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:OtherDiabetesCareMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278nvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMembercountry:CN2020-01-012020-12-310000353278nvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMembercountry:CN2019-01-012019-12-310000353278nvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMembercountry:CN2018-01-012018-12-310000353278nvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMembercountry:US2020-01-012020-12-310000353278nvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMembercountry:US2019-01-012019-12-310000353278nvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMembercountry:US2018-01-012018-12-310000353278nvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278nvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278nvo:TotalDiabetesCareMembernvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278nvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMembercountry:CN2020-01-012020-12-310000353278nvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMembercountry:CN2019-01-012019-12-310000353278nvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMembercountry:CN2018-01-012018-12-310000353278nvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMembercountry:US2020-01-012020-12-310000353278nvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMembercountry:US2019-01-012019-12-310000353278nvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMembercountry:US2018-01-012018-12-310000353278nvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278nvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278nvo:ObesitycareSaxendaMembernvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembercountry:CN2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembercountry:CN2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembercountry:CN2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMembercountry:US2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMembercountry:US2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMembercountry:US2018-01-012018-12-310000353278nvo:DiabetesAndObesityCareMember2020-01-012020-12-310000353278nvo:DiabetesAndObesityCareMember2019-01-012019-12-310000353278nvo:DiabetesAndObesityCareMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:BiopharmMembernvo:HaemophiliaMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:BiopharmMembernvo:HaemophiliaMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:BiopharmMembernvo:HaemophiliaMember2018-01-012018-12-310000353278nvo:BiopharmMembernvo:EMEAMembernvo:HaemophiliaMember2020-01-012020-12-310000353278nvo:BiopharmMembernvo:EMEAMembernvo:HaemophiliaMember2019-01-012019-12-310000353278nvo:BiopharmMembernvo:EMEAMembernvo:HaemophiliaMember2018-01-012018-12-310000353278nvo:BiopharmMembercountry:CNnvo:HaemophiliaMember2020-01-012020-12-310000353278nvo:BiopharmMembercountry:CNnvo:HaemophiliaMember2019-01-012019-12-310000353278nvo:BiopharmMembercountry:CNnvo:HaemophiliaMember2018-01-012018-12-310000353278nvo:BiopharmMembernvo:RestOfWorldMembernvo:HaemophiliaMember2020-01-012020-12-310000353278nvo:BiopharmMembernvo:RestOfWorldMembernvo:HaemophiliaMember2019-01-012019-12-310000353278nvo:BiopharmMembernvo:RestOfWorldMembernvo:HaemophiliaMember2018-01-012018-12-310000353278nvo:BiopharmMembersrt:NorthAmericaMembernvo:HaemophiliaMember2020-01-012020-12-310000353278nvo:BiopharmMembersrt:NorthAmericaMembernvo:HaemophiliaMember2019-01-012019-12-310000353278nvo:BiopharmMembersrt:NorthAmericaMembernvo:HaemophiliaMember2018-01-012018-12-310000353278nvo:BiopharmMembercountry:USnvo:HaemophiliaMember2020-01-012020-12-310000353278nvo:BiopharmMembercountry:USnvo:HaemophiliaMember2019-01-012019-12-310000353278nvo:BiopharmMembercountry:USnvo:HaemophiliaMember2018-01-012018-12-310000353278nvo:BiopharmMembernvo:HaemophiliaMember2020-01-012020-12-310000353278nvo:BiopharmMembernvo:HaemophiliaMember2019-01-012019-12-310000353278nvo:BiopharmMembernvo:HaemophiliaMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:NovoSevenMembernvo:BiopharmMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:NovoSevenMembernvo:BiopharmMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:NovoSevenMembernvo:BiopharmMember2018-01-012018-12-310000353278nvo:NovoSevenMembernvo:BiopharmMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:NovoSevenMembernvo:BiopharmMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:NovoSevenMembernvo:BiopharmMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:NovoSevenMembernvo:BiopharmMembercountry:CN2020-01-012020-12-310000353278nvo:NovoSevenMembernvo:BiopharmMembercountry:CN2019-01-012019-12-310000353278nvo:NovoSevenMembernvo:BiopharmMembercountry:CN2018-01-012018-12-310000353278nvo:NovoSevenMembernvo:BiopharmMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoSevenMembernvo:BiopharmMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:NovoSevenMembernvo:BiopharmMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:NovoSevenMembernvo:BiopharmMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:NovoSevenMembernvo:BiopharmMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:NovoSevenMembernvo:BiopharmMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:NovoSevenMembernvo:BiopharmMembercountry:US2020-01-012020-12-310000353278nvo:NovoSevenMembernvo:BiopharmMembercountry:US2019-01-012019-12-310000353278nvo:NovoSevenMembernvo:BiopharmMembercountry:US2018-01-012018-12-310000353278nvo:NovoSevenMembernvo:BiopharmMember2020-01-012020-12-310000353278nvo:NovoSevenMembernvo:BiopharmMember2019-01-012019-12-310000353278nvo:NovoSevenMembernvo:BiopharmMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:NovoEightMembernvo:BiopharmMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:NovoEightMembernvo:BiopharmMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:NovoEightMembernvo:BiopharmMember2018-01-012018-12-310000353278nvo:NovoEightMembernvo:BiopharmMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:NovoEightMembernvo:BiopharmMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:NovoEightMembernvo:BiopharmMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:NovoEightMembernvo:BiopharmMembercountry:CN2020-01-012020-12-310000353278nvo:NovoEightMembernvo:BiopharmMembercountry:CN2019-01-012019-12-310000353278nvo:NovoEightMembernvo:BiopharmMembercountry:CN2018-01-012018-12-310000353278nvo:NovoEightMembernvo:BiopharmMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoEightMembernvo:BiopharmMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:NovoEightMembernvo:BiopharmMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:NovoEightMembernvo:BiopharmMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:NovoEightMembernvo:BiopharmMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:NovoEightMembernvo:BiopharmMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:NovoEightMembernvo:BiopharmMembercountry:US2020-01-012020-12-310000353278nvo:NovoEightMembernvo:BiopharmMembercountry:US2019-01-012019-12-310000353278nvo:NovoEightMembernvo:BiopharmMembercountry:US2018-01-012018-12-310000353278nvo:NovoEightMembernvo:BiopharmMember2020-01-012020-12-310000353278nvo:NovoEightMembernvo:BiopharmMember2019-01-012019-12-310000353278nvo:NovoEightMembernvo:BiopharmMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:GrowthDisordersMembernvo:BiopharmMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:GrowthDisordersMembernvo:BiopharmMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:GrowthDisordersMembernvo:BiopharmMember2018-01-012018-12-310000353278nvo:GrowthDisordersMembernvo:BiopharmMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:GrowthDisordersMembernvo:BiopharmMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:GrowthDisordersMembernvo:BiopharmMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:GrowthDisordersMembernvo:BiopharmMembercountry:CN2020-01-012020-12-310000353278nvo:GrowthDisordersMembernvo:BiopharmMembercountry:CN2019-01-012019-12-310000353278nvo:GrowthDisordersMembernvo:BiopharmMembercountry:CN2018-01-012018-12-310000353278nvo:GrowthDisordersMembernvo:BiopharmMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:GrowthDisordersMembernvo:BiopharmMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:GrowthDisordersMembernvo:BiopharmMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:GrowthDisordersMembernvo:BiopharmMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:GrowthDisordersMembernvo:BiopharmMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:GrowthDisordersMembernvo:BiopharmMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:GrowthDisordersMembernvo:BiopharmMembercountry:US2020-01-012020-12-310000353278nvo:GrowthDisordersMembernvo:BiopharmMembercountry:US2019-01-012019-12-310000353278nvo:GrowthDisordersMembernvo:BiopharmMembercountry:US2018-01-012018-12-310000353278nvo:GrowthDisordersMembernvo:BiopharmMember2020-01-012020-12-310000353278nvo:GrowthDisordersMembernvo:BiopharmMember2019-01-012019-12-310000353278nvo:GrowthDisordersMembernvo:BiopharmMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:BiopharmMembernvo:OtherBiopharmProductsMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:BiopharmMembernvo:OtherBiopharmProductsMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:BiopharmMembernvo:OtherBiopharmProductsMember2018-01-012018-12-310000353278nvo:BiopharmMembernvo:OtherBiopharmProductsMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:BiopharmMembernvo:OtherBiopharmProductsMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:BiopharmMembernvo:OtherBiopharmProductsMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:BiopharmMembernvo:OtherBiopharmProductsMembercountry:CN2020-01-012020-12-310000353278nvo:BiopharmMembernvo:OtherBiopharmProductsMembercountry:CN2019-01-012019-12-310000353278nvo:BiopharmMembernvo:OtherBiopharmProductsMembercountry:CN2018-01-012018-12-310000353278nvo:BiopharmMembernvo:OtherBiopharmProductsMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:BiopharmMembernvo:OtherBiopharmProductsMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:BiopharmMembernvo:OtherBiopharmProductsMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:BiopharmMembernvo:OtherBiopharmProductsMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:BiopharmMembernvo:OtherBiopharmProductsMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:BiopharmMembernvo:OtherBiopharmProductsMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:BiopharmMembernvo:OtherBiopharmProductsMembercountry:US2020-01-012020-12-310000353278nvo:BiopharmMembernvo:OtherBiopharmProductsMembercountry:US2019-01-012019-12-310000353278nvo:BiopharmMembernvo:OtherBiopharmProductsMembercountry:US2018-01-012018-12-310000353278nvo:BiopharmMembernvo:OtherBiopharmProductsMember2020-01-012020-12-310000353278nvo:BiopharmMembernvo:OtherBiopharmProductsMember2019-01-012019-12-310000353278nvo:BiopharmMembernvo:OtherBiopharmProductsMember2018-01-012018-12-310000353278nvo:InternationalOperationsMembernvo:BiopharmMember2020-01-012020-12-310000353278nvo:InternationalOperationsMembernvo:BiopharmMember2019-01-012019-12-310000353278nvo:InternationalOperationsMembernvo:BiopharmMember2018-01-012018-12-310000353278nvo:BiopharmMembernvo:EMEAMember2020-01-012020-12-310000353278nvo:BiopharmMembernvo:EMEAMember2019-01-012019-12-310000353278nvo:BiopharmMembernvo:EMEAMember2018-01-012018-12-310000353278nvo:BiopharmMembercountry:CN2020-01-012020-12-310000353278nvo:BiopharmMembercountry:CN2019-01-012019-12-310000353278nvo:BiopharmMembercountry:CN2018-01-012018-12-310000353278nvo:BiopharmMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:BiopharmMembernvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:BiopharmMembernvo:RestOfWorldMember2018-01-012018-12-310000353278nvo:BiopharmMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:BiopharmMembersrt:NorthAmericaMember2019-01-012019-12-310000353278nvo:BiopharmMembersrt:NorthAmericaMember2018-01-012018-12-310000353278nvo:BiopharmMembercountry:US2020-01-012020-12-310000353278nvo:BiopharmMembercountry:US2019-01-012019-12-310000353278nvo:BiopharmMembercountry:US2018-01-012018-12-310000353278nvo:BiopharmMember2020-01-012020-12-310000353278nvo:BiopharmMember2019-01-012019-12-310000353278nvo:BiopharmMember2018-01-012018-12-310000353278nvo:InternationalOperationsMember2020-01-012020-12-310000353278nvo:InternationalOperationsMember2019-01-012019-12-310000353278nvo:InternationalOperationsMember2018-01-012018-12-310000353278nvo:EMEAMember2020-01-012020-12-310000353278nvo:EMEAMember2019-01-012019-12-310000353278nvo:EMEAMember2018-01-012018-12-310000353278country:CN2020-01-012020-12-310000353278country:CN2019-01-012019-12-310000353278country:CN2018-01-012018-12-310000353278nvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:RestOfWorldMember2019-01-012019-12-310000353278nvo:RestOfWorldMember2018-01-012018-12-310000353278country:US2020-01-012020-12-310000353278country:US2019-01-012019-12-310000353278country:US2018-01-012018-12-31nvo:employee0000353278nvo:Management1Member2020-01-012020-12-310000353278nvo:Management1Member2019-01-012019-12-310000353278nvo:Management1Member2018-01-012018-12-310000353278nvo:ExecutiveManagementMember2020-01-012020-12-310000353278nvo:ExecutiveManagementMember2019-01-012019-12-310000353278nvo:ExecutiveManagementMember2018-01-012018-12-310000353278nvo:BoardOfDirectorsMember2020-01-012020-12-310000353278nvo:BoardOfDirectorsMember2019-01-012019-12-310000353278nvo:BoardOfDirectorsMember2018-01-012018-12-310000353278nvo:RegisteredExecutiveManagementMember2020-01-012020-12-310000353278nvo:RegisteredExecutiveManagementMember2019-01-012019-12-310000353278nvo:RegisteredExecutiveManagementMember2018-01-012018-12-310000353278nvo:BeforeOffsetAmountMembernvo:PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember2019-12-310000353278nvo:BeforeOffsetAmountMembernvo:IntangibleAssetRelatedTemporaryDifferencesMember2019-12-310000353278nvo:BeforeOffsetAmountMembernvo:InventoryRelatedTemporaryDifferencesMember2019-12-310000353278nvo:BeforeOffsetAmountMembernvo:ProvisionsAndOtherLiabilitiesRelatedTemporaryDifferencesMember2019-12-310000353278nvo:BeforeOffsetAmountMembernvo:OtherTemporaryDifferencesAndUnusedTaxLossesMember2019-12-310000353278nvo:OffsetAmountMember2019-12-310000353278nvo:BeforeOffsetAmountMembernvo:PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember2020-01-012020-12-310000353278nvo:BeforeOffsetAmountMembernvo:IntangibleAssetRelatedTemporaryDifferencesMember2020-01-012020-12-310000353278nvo:BeforeOffsetAmountMembernvo:InventoryRelatedTemporaryDifferencesMember2020-01-012020-12-310000353278nvo:BeforeOffsetAmountMembernvo:ProvisionsAndOtherLiabilitiesRelatedTemporaryDifferencesMember2020-01-012020-12-310000353278nvo:BeforeOffsetAmountMembernvo:OtherTemporaryDifferencesAndUnusedTaxLossesMember2020-01-012020-12-310000353278nvo:BeforeOffsetAmountMembernvo:PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember2020-12-310000353278nvo:BeforeOffsetAmountMembernvo:IntangibleAssetRelatedTemporaryDifferencesMember2020-12-310000353278nvo:BeforeOffsetAmountMembernvo:InventoryRelatedTemporaryDifferencesMember2020-12-310000353278nvo:BeforeOffsetAmountMembernvo:ProvisionsAndOtherLiabilitiesRelatedTemporaryDifferencesMember2020-12-310000353278nvo:BeforeOffsetAmountMembernvo:OtherTemporaryDifferencesAndUnusedTaxLossesMember2020-12-310000353278nvo:OffsetAmountMember2020-12-310000353278nvo:BeforeOffsetAmountMembernvo:PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember2018-12-310000353278nvo:BeforeOffsetAmountMembernvo:IntangibleAssetRelatedTemporaryDifferencesMember2018-12-310000353278nvo:BeforeOffsetAmountMembernvo:InventoryRelatedTemporaryDifferencesMember2018-12-310000353278nvo:BeforeOffsetAmountMembernvo:ProvisionsAndOtherLiabilitiesRelatedTemporaryDifferencesMember2018-12-310000353278nvo:BeforeOffsetAmountMembernvo:OtherTemporaryDifferencesAndUnusedTaxLossesMember2018-12-310000353278nvo:OffsetAmountMember2018-12-310000353278nvo:BeforeOffsetAmountMembernvo:PropertyPlantAndEquipmentRelatedTemporaryDifferencesMembernvo:IFRS16Member2019-12-310000353278nvo:BeforeOffsetAmountMembernvo:IFRS16Membernvo:IntangibleAssetRelatedTemporaryDifferencesMember2019-12-310000353278nvo:BeforeOffsetAmountMembernvo:IFRS16Membernvo:InventoryRelatedTemporaryDifferencesMember2019-12-310000353278nvo:BeforeOffsetAmountMembernvo:ProvisionsAndOtherLiabilitiesRelatedTemporaryDifferencesMembernvo:IFRS16Member2019-12-310000353278nvo:BeforeOffsetAmountMembernvo:OtherTemporaryDifferencesAndUnusedTaxLossesMembernvo:IFRS16Member2019-12-310000353278nvo:IFRS16Member2019-12-310000353278nvo:BeforeOffsetAmountMembernvo:PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember2019-01-012019-12-310000353278nvo:BeforeOffsetAmountMembernvo:IntangibleAssetRelatedTemporaryDifferencesMember2019-01-012019-12-310000353278nvo:BeforeOffsetAmountMembernvo:InventoryRelatedTemporaryDifferencesMember2019-01-012019-12-310000353278nvo:BeforeOffsetAmountMembernvo:ProvisionsAndOtherLiabilitiesRelatedTemporaryDifferencesMember2019-01-012019-12-310000353278nvo:BeforeOffsetAmountMembernvo:OtherTemporaryDifferencesAndUnusedTaxLossesMember2019-01-012019-12-310000353278nvo:OffsetAmountMember2019-01-012019-12-310000353278ifrs-full:CountryOfDomicileMember2020-12-310000353278ifrs-full:CountryOfDomicileMember2019-12-310000353278country:US2020-12-310000353278country:US2019-12-310000353278ifrs-full:GrossCarryingAmountMembernvo:PatentsAndLicencesMember2019-12-310000353278nvo:SoftwareAndOtherIntangiblesMemberifrs-full:GrossCarryingAmountMember2019-12-310000353278ifrs-full:GrossCarryingAmountMember2019-12-310000353278ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2019-12-310000353278ifrs-full:GrossCarryingAmountMemberifrs-full:MachineryMember2019-12-310000353278ifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:GrossCarryingAmountMember2019-12-310000353278ifrs-full:ConstructionInProgressMemberifrs-full:GrossCarryingAmountMember2019-12-310000353278ifrs-full:GrossCarryingAmountMembernvo:PatentsAndLicencesMember2020-01-012020-12-310000353278nvo:SoftwareAndOtherIntangiblesMemberifrs-full:GrossCarryingAmountMember2020-01-012020-12-310000353278ifrs-full:GrossCarryingAmountMember2020-01-012020-12-310000353278ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2020-01-012020-12-310000353278ifrs-full:GrossCarryingAmountMemberifrs-full:MachineryMember2020-01-012020-12-310000353278ifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:GrossCarryingAmountMember2020-01-012020-12-310000353278ifrs-full:ConstructionInProgressMemberifrs-full:GrossCarryingAmountMember2020-01-012020-12-310000353278ifrs-full:GrossCarryingAmountMembernvo:PatentsAndLicencesMember2020-12-310000353278nvo:SoftwareAndOtherIntangiblesMemberifrs-full:GrossCarryingAmountMember2020-12-310000353278ifrs-full:GrossCarryingAmountMember2020-12-310000353278ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2020-12-310000353278ifrs-full:GrossCarryingAmountMemberifrs-full:MachineryMember2020-12-310000353278ifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:GrossCarryingAmountMember2020-12-310000353278ifrs-full:ConstructionInProgressMemberifrs-full:GrossCarryingAmountMember2020-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembernvo:PatentsAndLicencesMember2019-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembernvo:SoftwareAndOtherIntangiblesMember2019-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2019-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LandAndBuildingsMember2019-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MachineryMember2019-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherPropertyPlantAndEquipmentMember2019-12-310000353278ifrs-full:ConstructionInProgressMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2019-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembernvo:PatentsAndLicencesMember2020-01-012020-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembernvo:SoftwareAndOtherIntangiblesMember2020-01-012020-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-01-012020-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LandAndBuildingsMember2020-01-012020-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MachineryMember2020-01-012020-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherPropertyPlantAndEquipmentMember2020-01-012020-12-310000353278ifrs-full:ConstructionInProgressMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-01-012020-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembernvo:PatentsAndLicencesMember2020-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembernvo:SoftwareAndOtherIntangiblesMember2020-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LandAndBuildingsMember2020-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MachineryMember2020-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherPropertyPlantAndEquipmentMember2020-12-310000353278ifrs-full:ConstructionInProgressMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-12-310000353278nvo:PatentsAndLicencesMember2020-12-310000353278nvo:SoftwareAndOtherIntangiblesMember2020-12-310000353278ifrs-full:LandAndBuildingsMember2020-12-310000353278ifrs-full:MachineryMember2020-12-310000353278ifrs-full:OtherPropertyPlantAndEquipmentMember2020-12-310000353278ifrs-full:ConstructionInProgressMember2020-12-310000353278ifrs-full:GrossCarryingAmountMembernvo:PatentsAndLicencesMember2018-12-310000353278nvo:SoftwareAndOtherIntangiblesMemberifrs-full:GrossCarryingAmountMember2018-12-310000353278ifrs-full:GrossCarryingAmountMember2018-12-310000353278ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2018-12-310000353278ifrs-full:GrossCarryingAmountMemberifrs-full:MachineryMember2018-12-310000353278ifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:GrossCarryingAmountMember2018-12-310000353278ifrs-full:ConstructionInProgressMemberifrs-full:GrossCarryingAmountMember2018-12-310000353278ifrs-full:GrossCarryingAmountMembernvo:PatentsAndLicencesMember2019-01-012019-12-310000353278nvo:SoftwareAndOtherIntangiblesMemberifrs-full:GrossCarryingAmountMember2019-01-012019-12-310000353278ifrs-full:GrossCarryingAmountMemberifrs-full:IntangibleAssetsAndGoodwillMember2019-01-012019-12-310000353278ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2019-01-012019-12-310000353278ifrs-full:GrossCarryingAmountMemberifrs-full:MachineryMember2019-01-012019-12-310000353278ifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:GrossCarryingAmountMember2019-01-012019-12-310000353278ifrs-full:ConstructionInProgressMemberifrs-full:GrossCarryingAmountMember2019-01-012019-12-310000353278ifrs-full:GrossCarryingAmountMember2019-01-012019-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembernvo:PatentsAndLicencesMember2018-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembernvo:SoftwareAndOtherIntangiblesMember2018-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2018-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LandAndBuildingsMember2018-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MachineryMember2018-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherPropertyPlantAndEquipmentMember2018-12-310000353278ifrs-full:ConstructionInProgressMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2018-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembernvo:PatentsAndLicencesMember2019-01-012019-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembernvo:SoftwareAndOtherIntangiblesMember2019-01-012019-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2019-01-012019-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LandAndBuildingsMember2019-01-012019-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MachineryMember2019-01-012019-12-310000353278ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherPropertyPlantAndEquipmentMember2019-01-012019-12-310000353278ifrs-full:ConstructionInProgressMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2019-01-012019-12-310000353278nvo:PatentsAndLicencesMember2019-12-310000353278nvo:SoftwareAndOtherIntangiblesMember2019-12-310000353278ifrs-full:LandAndBuildingsMember2019-12-310000353278ifrs-full:MachineryMember2019-12-310000353278ifrs-full:OtherPropertyPlantAndEquipmentMember2019-12-310000353278ifrs-full:ConstructionInProgressMember2019-12-310000353278nvo:CostOfSales1Member2020-01-012020-12-310000353278nvo:CostOfSales1Member2019-01-012019-12-310000353278nvo:CostOfSales1Member2018-01-012018-12-310000353278nvo:SellingExpenseAndDistributionCostsMember2020-01-012020-12-310000353278nvo:SellingExpenseAndDistributionCostsMember2019-01-012019-12-310000353278nvo:SellingExpenseAndDistributionCostsMember2018-01-012018-12-310000353278nvo:ResearchAndDevelopmentExpense1Member2020-01-012020-12-310000353278nvo:ResearchAndDevelopmentExpense1Member2019-01-012019-12-310000353278nvo:ResearchAndDevelopmentExpense1Member2018-01-012018-12-310000353278nvo:AdministrativeExpenseMember2020-01-012020-12-310000353278nvo:AdministrativeExpenseMember2019-01-012019-12-310000353278nvo:AdministrativeExpenseMember2018-01-012018-12-310000353278nvo:OtherOperatingIncomeExpense1Member2020-01-012020-12-310000353278nvo:OtherOperatingIncomeExpense1Member2019-01-012019-12-310000353278nvo:OtherOperatingIncomeExpense1Member2018-01-012018-12-310000353278nvo:CorvidiaTherapeuticsIncMember2020-01-012020-12-31iso4217:USD0000353278nvo:EmisphereTechnologiesMember2020-01-012020-12-310000353278nvo:MHRFundManagementMember2020-01-012020-12-310000353278nvo:EmisphereTechnologiesMembernvo:PatentsAndLicencesMember2020-01-012020-12-310000353278nvo:EmisphereTechnologiesMemberifrs-full:GrossCarryingAmountMember2020-12-310000353278ifrs-full:InternallyGeneratedMember2020-01-012020-12-310000353278ifrs-full:InternallyGeneratedMember2019-01-012019-12-310000353278ifrs-full:TopOfRangeMembernvo:PatentsAndLicencesMember2020-01-012020-12-310000353278ifrs-full:BottomOfRangeMemberifrs-full:ComputerSoftwareMember2020-01-012020-12-310000353278ifrs-full:ComputerSoftwareMemberifrs-full:TopOfRangeMember2020-01-012020-12-310000353278nvo:PatentsAndLicencesMember2020-01-012020-12-310000353278nvo:PatentsAndLicencesMember2019-01-012019-12-310000353278ifrs-full:BottomOfRangeMemberifrs-full:BuildingsMember2020-01-012020-12-310000353278ifrs-full:TopOfRangeMemberifrs-full:BuildingsMember2020-01-012020-12-310000353278ifrs-full:BottomOfRangeMemberifrs-full:MachineryMember2020-01-012020-12-310000353278ifrs-full:MachineryMemberifrs-full:TopOfRangeMember2020-01-012020-12-310000353278ifrs-full:BottomOfRangeMemberifrs-full:OtherPropertyPlantAndEquipmentMember2020-01-012020-12-310000353278ifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:TopOfRangeMember2020-01-012020-12-310000353278ifrs-full:LandAndBuildingsMember2019-12-310000353278ifrs-full:OtherPropertyPlantAndEquipmentMember2019-12-310000353278ifrs-full:LandAndBuildingsMember2020-01-012020-12-310000353278ifrs-full:OtherPropertyPlantAndEquipmentMember2020-01-012020-12-310000353278ifrs-full:LandAndBuildingsMember2020-12-310000353278ifrs-full:OtherPropertyPlantAndEquipmentMember2020-12-310000353278ifrs-full:LandAndBuildingsMember2018-12-310000353278ifrs-full:OtherPropertyPlantAndEquipmentMember2018-12-310000353278ifrs-full:LandAndBuildingsMember2019-01-012019-12-310000353278ifrs-full:OtherPropertyPlantAndEquipmentMember2019-01-012019-12-310000353278ifrs-full:AccumulatedImpairmentMember2020-12-310000353278ifrs-full:AccumulatedImpairmentMember2019-12-310000353278ifrs-full:AccumulatedImpairmentMember2018-12-310000353278nvo:PrelaunchInventoryMember2019-01-012019-12-310000353278ifrs-full:CurrentMemberifrs-full:TradeReceivablesMember2020-12-310000353278ifrs-full:TradeReceivablesMembernvo:LaterthanonedayandnotlaterthanthreemonthsMember2020-12-310000353278ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMemberifrs-full:TradeReceivablesMember2020-12-310000353278nvo:LaterthansixmonthsandnotlaterthanninemonthsMemberifrs-full:TradeReceivablesMember2020-12-310000353278nvo:LaterthanninemonthsandnotlaterthanoneyearMemberifrs-full:TradeReceivablesMember2020-12-310000353278ifrs-full:TradeReceivablesMemberifrs-full:LaterThanOneYearMember2020-12-310000353278ifrs-full:TradeReceivablesMember2020-12-310000353278nvo:EMEAMemberifrs-full:TradeReceivablesMember2020-12-310000353278country:CNifrs-full:TradeReceivablesMember2020-12-310000353278nvo:RestOfWorldMemberifrs-full:TradeReceivablesMember2020-12-310000353278srt:NorthAmericaMemberifrs-full:TradeReceivablesMember2020-12-310000353278ifrs-full:CurrentMemberifrs-full:TradeReceivablesMember2019-12-310000353278ifrs-full:TradeReceivablesMembernvo:LaterthanonedayandnotlaterthanthreemonthsMember2019-12-310000353278ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMemberifrs-full:TradeReceivablesMember2019-12-310000353278nvo:LaterthansixmonthsandnotlaterthanninemonthsMemberifrs-full:TradeReceivablesMember2019-12-310000353278nvo:LaterthanninemonthsandnotlaterthanoneyearMemberifrs-full:TradeReceivablesMember2019-12-310000353278ifrs-full:TradeReceivablesMemberifrs-full:LaterThanOneYearMember2019-12-310000353278ifrs-full:TradeReceivablesMember2019-12-310000353278nvo:EMEAMemberifrs-full:TradeReceivablesMember2019-12-310000353278country:CNifrs-full:TradeReceivablesMember2019-12-310000353278nvo:RestOfWorldMemberifrs-full:TradeReceivablesMember2019-12-310000353278srt:NorthAmericaMemberifrs-full:TradeReceivablesMember2019-12-310000353278ifrs-full:TradeReceivablesMember2018-12-310000353278ifrs-full:TradeReceivablesMember2020-01-012020-12-310000353278ifrs-full:TradeReceivablesMember2019-01-012019-12-310000353278ifrs-full:PresentValueOfDefinedBenefitObligationMember2020-12-310000353278ifrs-full:PresentValueOfDefinedBenefitObligationMember2019-12-310000353278ifrs-full:PlanAssetsMember2020-12-310000353278ifrs-full:PlanAssetsMember2019-12-310000353278ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember2020-12-310000353278ifrs-full:ActuarialAssumptionOfDiscountRatesMember2020-12-310000353278ifrs-full:ActuarialAssumptionOfDiscountRatesMember2019-12-310000353278ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember2019-12-310000353278nvo:PartlyFundedPlanMember2020-12-310000353278nvo:PartlyFundedPlanMember2019-12-310000353278nvo:UnfundedPlan1Member2020-12-310000353278nvo:UnfundedPlan1Member2019-12-310000353278ifrs-full:LegalProceedingsProvisionMember2019-12-310000353278ifrs-full:RefundsProvisionMember2019-12-310000353278ifrs-full:MiscellaneousOtherProvisionsMember2019-12-310000353278ifrs-full:LegalProceedingsProvisionMember2020-01-012020-12-310000353278ifrs-full:RefundsProvisionMember2020-01-012020-12-310000353278ifrs-full:MiscellaneousOtherProvisionsMember2020-01-012020-12-310000353278ifrs-full:LegalProceedingsProvisionMember2020-12-310000353278ifrs-full:RefundsProvisionMember2020-12-310000353278ifrs-full:MiscellaneousOtherProvisionsMember2020-12-31nvo:plaintiff00003532782021-02-030000353278ifrs-full:LegalProceedingsContingentLiabilityMember2019-08-012019-08-31nvo:lawsuit0000353278stpr:NJ2020-12-310000353278stpr:KY2020-12-31nvo:numberOfMotionsxbrli:shares00003532782020-08-012020-08-3100003532782020-03-012020-03-310000353278ifrs-full:TreasurySharesMember2020-12-310000353278ifrs-full:TreasurySharesMember2019-12-310000353278nvo:TreasurySharesMarketValueMember2019-12-310000353278nvo:BShareCapitalMembernvo:TreasurySharesMarketValueMember2019-12-310000353278nvo:BShareCapitalMembernvo:TreasurySharesMarketValueMember2018-12-310000353278nvo:TreasurySharesMarketValueMember2020-01-012020-12-310000353278nvo:BShareCapitalMembernvo:TreasurySharesMarketValueMember2020-01-012020-12-310000353278nvo:BShareCapitalMembernvo:TreasurySharesMarketValueMember2019-01-012019-12-310000353278nvo:TreasurySharesMarketValueMember2020-12-310000353278nvo:BShareCapitalMembernvo:TreasurySharesMarketValueMember2020-12-310000353278nvo:ShareRepurchaseProgrammeOfNovoNordiskBSharesMember2019-12-310000353278nvo:ShareRepurchaseProgrammeOfNovoNordiskBSharesMember2020-12-310000353278ifrs-full:IssuedCapitalMembernvo:AShareCapitalMember2017-12-310000353278ifrs-full:IssuedCapitalMembernvo:BShareCapitalMember2017-12-310000353278ifrs-full:IssuedCapitalMembernvo:AShareCapitalMember2018-01-012018-12-310000353278ifrs-full:IssuedCapitalMembernvo:BShareCapitalMember2018-01-012018-12-310000353278ifrs-full:IssuedCapitalMembernvo:AShareCapitalMember2019-01-012019-12-310000353278ifrs-full:IssuedCapitalMembernvo:BShareCapitalMember2019-01-012019-12-310000353278ifrs-full:IssuedCapitalMembernvo:AShareCapitalMember2019-12-310000353278ifrs-full:IssuedCapitalMembernvo:BShareCapitalMember2019-12-310000353278ifrs-full:IssuedCapitalMembernvo:AShareCapitalMember2020-01-012020-12-310000353278ifrs-full:IssuedCapitalMembernvo:BShareCapitalMember2020-01-012020-12-310000353278ifrs-full:IssuedCapitalMembernvo:AShareCapitalMember2020-12-310000353278ifrs-full:IssuedCapitalMembernvo:BShareCapitalMember2020-12-31nvo:vote0000353278ifrs-full:ReserveOfExchangeDifferencesOnTranslationMemberifrs-full:OtherReservesMember2017-12-310000353278ifrs-full:ReserveOfCashFlowHedgesMemberifrs-full:OtherReservesMember2017-12-310000353278ifrs-full:MiscellaneousOtherReservesMemberifrs-full:OtherReservesMember2017-12-310000353278ifrs-full:ReserveOfExchangeDifferencesOnTranslationMemberifrs-full:OtherReservesMember2018-01-012018-12-310000353278ifrs-full:ReserveOfCashFlowHedgesMemberifrs-full:OtherReservesMember2018-01-012018-12-310000353278ifrs-full:MiscellaneousOtherReservesMemberifrs-full:OtherReservesMember2018-01-012018-12-310000353278ifrs-full:ReserveOfExchangeDifferencesOnTranslationMemberifrs-full:OtherReservesMember2018-12-310000353278ifrs-full:ReserveOfCashFlowHedgesMemberifrs-full:OtherReservesMember2018-12-310000353278ifrs-full:MiscellaneousOtherReservesMemberifrs-full:OtherReservesMember2018-12-310000353278ifrs-full:ReserveOfExchangeDifferencesOnTranslationMemberifrs-full:OtherReservesMember2019-01-012019-12-310000353278ifrs-full:ReserveOfCashFlowHedgesMemberifrs-full:OtherReservesMember2019-01-012019-12-310000353278ifrs-full:MiscellaneousOtherReservesMemberifrs-full:OtherReservesMember2019-01-012019-12-310000353278ifrs-full:ReserveOfExchangeDifferencesOnTranslationMemberifrs-full:OtherReservesMember2019-12-310000353278ifrs-full:ReserveOfCashFlowHedgesMemberifrs-full:OtherReservesMember2019-12-310000353278ifrs-full:MiscellaneousOtherReservesMemberifrs-full:OtherReservesMember2019-12-310000353278ifrs-full:ReserveOfExchangeDifferencesOnTranslationMemberifrs-full:OtherReservesMember2020-01-012020-12-310000353278ifrs-full:ReserveOfCashFlowHedgesMemberifrs-full:OtherReservesMember2020-01-012020-12-310000353278ifrs-full:MiscellaneousOtherReservesMemberifrs-full:OtherReservesMember2020-01-012020-12-310000353278ifrs-full:ReserveOfExchangeDifferencesOnTranslationMemberifrs-full:OtherReservesMember2020-12-310000353278ifrs-full:ReserveOfCashFlowHedgesMemberifrs-full:OtherReservesMember2020-12-310000353278ifrs-full:MiscellaneousOtherReservesMemberifrs-full:OtherReservesMember2020-12-310000353278ifrs-full:TopOfRangeMember2020-01-012020-12-310000353278ifrs-full:BottomOfRangeMembernvo:USDCNYJPYGBPAndCADMember2020-01-012020-12-310000353278nvo:USDCNYJPYGBPAndCADMemberifrs-full:TopOfRangeMember2020-01-012020-12-310000353278currency:USD2020-01-012020-12-310000353278currency:USD2019-01-012019-12-310000353278currency:CNY2020-01-012020-12-310000353278currency:CNY2019-01-012019-12-310000353278currency:JPY2020-01-012020-12-310000353278currency:JPY2019-01-012019-12-310000353278currency:CAD2020-01-012020-12-310000353278currency:CAD2019-01-012019-12-310000353278currency:GBP2020-01-012020-12-310000353278currency:GBP2019-01-012019-12-31iso4217:DKKiso4217:USD0000353278currency:USDifrs-full:CurrencyRiskMember2020-01-012020-12-310000353278currency:USDifrs-full:CurrencyRiskMember2019-01-012019-12-310000353278currency:USDifrs-full:CurrencyRiskMember2018-01-012018-12-310000353278currency:USDifrs-full:CurrencyRiskMember2020-12-310000353278currency:USDifrs-full:CurrencyRiskMember2019-12-310000353278currency:USDifrs-full:CurrencyRiskMember2018-12-31iso4217:DKKiso4217:CNY0000353278currency:CNYifrs-full:CurrencyRiskMember2020-01-012020-12-310000353278currency:CNYifrs-full:CurrencyRiskMember2019-01-012019-12-310000353278currency:CNYifrs-full:CurrencyRiskMember2018-01-012018-12-310000353278currency:CNYifrs-full:CurrencyRiskMember2020-12-310000353278currency:CNYifrs-full:CurrencyRiskMember2019-12-310000353278currency:CNYifrs-full:CurrencyRiskMember2018-12-31iso4217:DKKiso4217:JPY0000353278ifrs-full:CurrencyRiskMembercurrency:JPY2020-01-012020-12-310000353278ifrs-full:CurrencyRiskMembercurrency:JPY2019-01-012019-12-310000353278ifrs-full:CurrencyRiskMembercurrency:JPY2018-01-012018-12-310000353278ifrs-full:CurrencyRiskMembercurrency:JPY2020-12-310000353278ifrs-full:CurrencyRiskMembercurrency:JPY2019-12-310000353278ifrs-full:CurrencyRiskMembercurrency:JPY2018-12-31iso4217:DKKiso4217:CAD0000353278ifrs-full:CurrencyRiskMembercurrency:CAD2020-01-012020-12-310000353278ifrs-full:CurrencyRiskMembercurrency:CAD2019-01-012019-12-310000353278ifrs-full:CurrencyRiskMembercurrency:CAD2018-01-012018-12-310000353278ifrs-full:CurrencyRiskMembercurrency:CAD2020-12-310000353278ifrs-full:CurrencyRiskMembercurrency:CAD2019-12-310000353278ifrs-full:CurrencyRiskMembercurrency:CAD2018-12-31iso4217:DKKiso4217:GBP0000353278currency:GBPifrs-full:CurrencyRiskMember2020-01-012020-12-310000353278currency:GBPifrs-full:CurrencyRiskMember2019-01-012019-12-310000353278currency:GBPifrs-full:CurrencyRiskMember2018-01-012018-12-310000353278currency:GBPifrs-full:CurrencyRiskMember2020-12-310000353278currency:GBPifrs-full:CurrencyRiskMember2019-12-310000353278currency:GBPifrs-full:CurrencyRiskMember2018-12-310000353278ifrs-full:CurrencyRiskMember2020-01-012020-12-310000353278ifrs-full:CurrencyRiskMembernvo:EffectOf5IncreaseInAllOtherCurrenciesMember2020-01-012020-12-310000353278nvo:EffectOf5DecreaseInAllOtherCurrenciesMemberifrs-full:CurrencyRiskMember2020-01-012020-12-310000353278ifrs-full:CurrencyRiskMembernvo:EffectOf5IncreaseInAllOtherCurrenciesMember2019-01-012019-12-310000353278nvo:EffectOf5DecreaseInAllOtherCurrenciesMemberifrs-full:CurrencyRiskMember2019-01-012019-12-310000353278currency:USDifrs-full:CurrencyRiskMembernvo:EffectOf5IncreaseInAllOtherCurrenciesMember2020-01-012020-12-310000353278currency:USDifrs-full:CurrencyRiskMembernvo:EffectOf5IncreaseInAllOtherCurrenciesMember2019-01-012019-12-310000353278nvo:FinancialCounterpartiesMemberifrs-full:CreditRiskMember2020-12-310000353278nvo:FinancialCounterpartiesMemberifrs-full:CreditRiskMember2019-12-310000353278nvo:TradeReceivablesOtherReceivablesLessPrepaymentsAndVATAndOtherFinancialAssetsMemberifrs-full:CreditRiskMember2020-12-310000353278nvo:TradeReceivablesOtherReceivablesLessPrepaymentsAndVATAndOtherFinancialAssetsMemberifrs-full:CreditRiskMember2019-12-310000353278nvo:CashAtBankMembernvo:StandardPoorsMoodysAndFitchAARangeMember2020-12-310000353278ifrs-full:DerivativesMembernvo:StandardPoorsMoodysAndFitchAARangeMember2020-12-310000353278nvo:StandardPoorsMoodysAndFitchAARangeMember2020-12-310000353278nvo:StandardPoorsMoodysAndFitchARangeMembernvo:CashAtBankMember2020-12-310000353278ifrs-full:DerivativesMembernvo:StandardPoorsMoodysAndFitchARangeMember2020-12-310000353278nvo:StandardPoorsMoodysAndFitchARangeMember2020-12-310000353278nvo:StandardPoorsMoodysAndFitchBBBRangeMembernvo:CashAtBankMember2020-12-310000353278nvo:StandardPoorsMoodysAndFitchBBBRangeMemberifrs-full:DerivativesMember2020-12-310000353278nvo:StandardPoorsMoodysAndFitchBBBRangeMember2020-12-310000353278nvo:StandardPoorsMoodysAndFitchNotRatedOrBelowBBBRangeMembernvo:CashAtBankMember2020-12-310000353278ifrs-full:DerivativesMembernvo:StandardPoorsMoodysAndFitchNotRatedOrBelowBBBRangeMember2020-12-310000353278nvo:StandardPoorsMoodysAndFitchNotRatedOrBelowBBBRangeMember2020-12-310000353278nvo:CashAtBankMember2020-12-310000353278ifrs-full:DerivativesMember2020-12-310000353278nvo:CashAtBankMembernvo:StandardPoorsMoodysAndFitchAARangeMember2019-12-310000353278ifrs-full:DerivativesMembernvo:StandardPoorsMoodysAndFitchAARangeMember2019-12-310000353278nvo:StandardPoorsMoodysAndFitchAARangeMember2019-12-310000353278nvo:StandardPoorsMoodysAndFitchARangeMembernvo:CashAtBankMember2019-12-310000353278ifrs-full:DerivativesMembernvo:StandardPoorsMoodysAndFitchARangeMember2019-12-310000353278nvo:StandardPoorsMoodysAndFitchARangeMember2019-12-310000353278nvo:StandardPoorsMoodysAndFitchBBBRangeMembernvo:CashAtBankMember2019-12-310000353278nvo:StandardPoorsMoodysAndFitchBBBRangeMemberifrs-full:DerivativesMember2019-12-310000353278nvo:StandardPoorsMoodysAndFitchBBBRangeMember2019-12-310000353278nvo:StandardPoorsMoodysAndFitchNotRatedOrBelowBBBRangeMembernvo:CashAtBankMember2019-12-310000353278ifrs-full:DerivativesMembernvo:StandardPoorsMoodysAndFitchNotRatedOrBelowBBBRangeMember2019-12-310000353278nvo:StandardPoorsMoodysAndFitchNotRatedOrBelowBBBRangeMember2019-12-310000353278nvo:CashAtBankMember2019-12-310000353278ifrs-full:DerivativesMember2019-12-310000353278ifrs-full:FactoringOfReceivablesMemberifrs-full:LaterThanOneYearMembercountry:US2020-12-310000353278ifrs-full:FactoringOfReceivablesMemberifrs-full:LaterThanOneYearMembercountry:US2019-12-310000353278ifrs-full:FactoringOfReceivablesMemberifrs-full:LaterThanOneYearMembercountry:US2018-12-310000353278ifrs-full:FactoringOfReceivablesMemberifrs-full:LaterThanOneYearMembercountry:JP2020-12-310000353278ifrs-full:FactoringOfReceivablesMemberifrs-full:LaterThanOneYearMembercountry:JP2019-12-310000353278ifrs-full:FactoringOfReceivablesMemberifrs-full:LaterThanOneYearMembercountry:JP2018-12-310000353278ifrs-full:ForwardContractMemberifrs-full:CashFlowHedgesMembercurrency:USD2020-12-310000353278ifrs-full:ForwardContractMemberifrs-full:CashFlowHedgesMembercurrency:USD2019-12-310000353278ifrs-full:ForwardContractMemberifrs-full:CashFlowHedgesMembernvo:CNHJPYGBPAndCADMember2020-12-310000353278ifrs-full:ForwardContractMemberifrs-full:CashFlowHedgesMembernvo:CNHJPYGBPAndCADMember2019-12-310000353278ifrs-full:ForwardContractMemberifrs-full:CashFlowHedgesMember2020-12-310000353278ifrs-full:ForwardContractMemberifrs-full:CashFlowHedgesMember2019-12-310000353278ifrs-full:ForwardContractMembercurrency:USDifrs-full:FairValueHedgesMember2020-12-310000353278ifrs-full:ForwardContractMembercurrency:USDifrs-full:FairValueHedgesMember2019-12-310000353278ifrs-full:ForwardContractMemberifrs-full:FairValueHedgesMembernvo:CNHCADEURGBPAndJPYMember2020-12-310000353278ifrs-full:ForwardContractMemberifrs-full:FairValueHedgesMembernvo:CNHCADEURGBPAndJPYMember2019-12-310000353278ifrs-full:ForwardContractMemberifrs-full:FairValueHedgesMember2020-12-310000353278ifrs-full:ForwardContractMemberifrs-full:FairValueHedgesMember2019-12-310000353278ifrs-full:DerivativesMember2020-01-012020-12-310000353278ifrs-full:DerivativesMember2020-01-012020-12-310000353278ifrs-full:DerivativesMember2019-01-012019-12-310000353278ifrs-full:DerivativesMember2019-01-012019-12-310000353278ifrs-full:CashFlowHedgesMemberifrs-full:OtherIntangibleAssetsMember2020-01-012020-12-310000353278ifrs-full:CashFlowHedgesMember2020-01-012020-12-310000353278ifrs-full:NotLaterThanOneYearMember2020-12-310000353278nvo:BankOverdraftsMemberifrs-full:NotLaterThanOneYearMember2020-12-310000353278ifrs-full:NotLaterThanOneYearMember2019-12-310000353278nvo:BankOverdraftsMemberifrs-full:NotLaterThanOneYearMember2019-12-310000353278ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2020-12-310000353278nvo:BankOverdraftsMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2020-12-310000353278ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2019-12-310000353278nvo:BankOverdraftsMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2019-12-310000353278ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2020-12-310000353278ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMembernvo:BankOverdraftsMember2020-12-310000353278ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2019-12-310000353278ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMembernvo:BankOverdraftsMember2019-12-310000353278ifrs-full:LaterThanFiveYearsMember2020-12-310000353278nvo:BankOverdraftsMemberifrs-full:LaterThanFiveYearsMember2020-12-310000353278ifrs-full:LaterThanFiveYearsMember2019-12-310000353278nvo:BankOverdraftsMemberifrs-full:LaterThanFiveYearsMember2019-12-310000353278nvo:BankOverdraftsMember2020-12-310000353278nvo:BankOverdraftsMember2019-12-310000353278ifrs-full:LeaseLiabilitiesMember2019-12-310000353278ifrs-full:LeaseLiabilitiesMember2020-01-012020-12-310000353278ifrs-full:LeaseLiabilitiesMember2020-12-310000353278nvo:LoansMember2019-12-310000353278nvo:LoansMember2020-01-012020-12-310000353278nvo:LoansMember2020-12-310000353278nvo:BankOverdraftsMember2019-12-310000353278nvo:BankOverdraftsMember2020-01-012020-12-310000353278nvo:BankOverdraftsMember2020-12-310000353278nvo:LiabilitiesArisingFromFinancingActivitiesTotalMember2019-12-310000353278nvo:LiabilitiesArisingFromFinancingActivitiesTotalMember2020-01-012020-12-310000353278nvo:LiabilitiesArisingFromFinancingActivitiesTotalMember2020-12-310000353278nvo:BankOverdraftsLiabilitiesNotArisingFromFinancingActivitiesMember2019-12-310000353278nvo:BankOverdraftsLiabilitiesNotArisingFromFinancingActivitiesMember2020-01-012020-12-310000353278nvo:BankOverdraftsLiabilitiesNotArisingFromFinancingActivitiesMember2020-12-310000353278ifrs-full:LeaseLiabilitiesMember2018-12-310000353278ifrs-full:LeaseLiabilitiesMember2019-01-012019-12-310000353278nvo:BankOverdraftsMember2018-12-310000353278nvo:BankOverdraftsMember2019-01-012019-12-310000353278nvo:LiabilitiesArisingFromFinancingActivitiesTotalMember2018-12-310000353278nvo:LiabilitiesArisingFromFinancingActivitiesTotalMember2019-01-012019-12-310000353278nvo:BankOverdraftsLiabilitiesNotArisingFromFinancingActivitiesMember2018-12-310000353278nvo:BankOverdraftsLiabilitiesNotArisingFromFinancingActivitiesMember2019-01-012019-12-31iso4217:EUR0000353278nvo:EURUndrawnCommittedCreditFacilityMember2020-12-310000353278nvo:EURUndrawnCommittedCreditFacilityMember2019-12-310000353278nvo:EURUndrawnCommittedCreditFacilityMember2018-12-310000353278ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMembernvo:OtherFinancialAssetsMember2020-12-310000353278ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMembernvo:OtherFinancialAssetsMember2019-12-310000353278ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:DerivativesMember2020-12-310000353278ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:DerivativesMember2019-12-310000353278ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2020-12-310000353278ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2019-12-310000353278ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembernvo:OtherFinancialAssetsMember2020-12-310000353278ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembernvo:OtherFinancialAssetsMember2019-12-310000353278ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberifrs-full:TradeReceivablesMember2020-12-310000353278ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberifrs-full:TradeReceivablesMember2019-12-310000353278nvo:OtherReceivablesMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2020-12-310000353278nvo:OtherReceivablesMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2019-12-310000353278nvo:PrepaymentsAndVATReceivablesMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2020-12-310000353278nvo:PrepaymentsAndVATReceivablesMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2019-12-310000353278ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembernvo:CashAtBankMember2020-12-310000353278ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembernvo:CashAtBankMember2019-12-310000353278ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2020-12-310000353278ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2019-12-310000353278ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrs-full:TradeReceivablesMember2020-12-310000353278ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrs-full:TradeReceivablesMember2019-12-310000353278ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember2020-12-310000353278ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember2019-12-310000353278ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembernvo:OtherFinancialAssetsOtherReceivablesNonCurrentAndPrepaymentsMember2020-12-310000353278ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembernvo:OtherFinancialAssetsOtherReceivablesNonCurrentAndPrepaymentsMember2019-12-310000353278ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:DerivativesMember2020-12-310000353278ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:DerivativesMember2019-12-310000353278ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-12-310000353278ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2019-12-310000353278ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMembernvo:BorrowingsNoncurrentMember2020-12-310000353278ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMembernvo:BorrowingsNoncurrentMember2019-12-310000353278ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMembernvo:BorrowingsCurrentMember2020-12-310000353278ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMembernvo:BorrowingsCurrentMember2019-12-310000353278nvo:TradePayablesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2020-12-310000353278nvo:TradePayablesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2019-12-310000353278ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMembernvo:OtherLiabilities1Member2020-12-310000353278ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMembernvo:OtherLiabilities1Member2019-12-310000353278ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMembernvo:VATAndDutiesPayableMember2020-12-310000353278ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMembernvo:VATAndDutiesPayableMember2019-12-310000353278ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2020-12-310000353278ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2019-12-310000353278ifrs-full:Level1OfFairValueHierarchyMember2020-12-310000353278ifrs-full:Level1OfFairValueHierarchyMember2019-12-310000353278ifrs-full:Level2OfFairValueHierarchyMember2020-12-310000353278ifrs-full:Level2OfFairValueHierarchyMember2019-12-310000353278ifrs-full:Level3OfFairValueHierarchyMember2020-12-310000353278ifrs-full:Level3OfFairValueHierarchyMember2019-12-310000353278nvo:RestrictedStockUnitsToEmployeesMember2020-01-012020-12-310000353278nvo:RestrictedStockUnitsToEmployeesMember2019-01-012019-12-310000353278nvo:RestrictedStockUnitsToEmployeesMember2018-01-012018-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMember2020-01-012020-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMember2019-01-012019-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMember2018-01-012018-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementGroupBelowSeniorManagementBoardMember2020-01-012020-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementGroupBelowSeniorManagementBoardMember2019-01-012019-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementGroupBelowSeniorManagementBoardMember2018-01-012018-12-310000353278nvo:SharesAllocatedtoIndividualEmployeesMember2020-01-012020-12-310000353278nvo:SharesAllocatedtoIndividualEmployeesMember2019-01-012019-12-310000353278nvo:SharesAllocatedtoIndividualEmployeesMember2018-01-012018-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMember2017-01-012017-12-310000353278nvo:RestrictedStockUnitsToEmployeesMember2019-08-010000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMembernvo:AwardDatePeriodSixMember2020-01-012020-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMembernvo:AwardDatePeriodSixMember2020-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMembernvo:SharebasedCompensationAwardTrancheOneMembernvo:AwardDatePeriodSixMember2020-01-012020-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMembernvo:NovoNordiskBSharesMember2019-02-012019-02-280000353278nvo:ExecutiveManagementMembernvo:LongTermShareBasedIncentiveProgrammeManagementBoardMember2020-02-052020-02-190000353278nvo:SeniorManagementBoardMembernvo:LongTermShareBasedIncentiveProgrammeManagementBoardMember2020-02-052020-02-190000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMembernvo:AwardDatePeriodThreeMember2020-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMembernvo:AwardDatePeriodThreeMember2020-01-012020-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementGroupBelowSeniorManagementBoardMembernvo:AwardDatePeriodSixMember2020-01-012020-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementGroupBelowSeniorManagementBoardMembernvo:AwardDatePeriodSixMember2020-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementGroupBelowSeniorManagementBoardMembernvo:SharebasedCompensationAwardTrancheOneMembernvo:AwardDatePeriodSixMember2020-01-012020-12-310000353278nvo:AwardDatePeriodSixMembernvo:LongTermShareBasedIncentiveProgrammeBelowManagementBoardMember2020-01-012020-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementGroupBelowSeniorManagementBoardMembernvo:SharebasedCompensationAwardTrancheThreeMembernvo:AwardDatePeriodThreeMember2020-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementGroupBelowSeniorManagementBoardMembernvo:AwardDatePeriodThreeMember2020-12-310000353278nvo:AwardDatePeriodSixMembernvo:RestrictedStockUnitsToEmployeesMember2019-01-012019-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMembernvo:AwardDatePeriodSevenMember2020-01-012020-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMembernvo:AwardDatePeriodSixMember2019-01-012019-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMembernvo:AwardDatePeriodFiveMember2018-01-012018-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementGroupBelowSeniorManagementBoardMembernvo:AwardDatePeriodSevenMember2020-01-012020-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementGroupBelowSeniorManagementBoardMembernvo:AwardDatePeriodSixMember2019-01-012019-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementGroupBelowSeniorManagementBoardMembernvo:AwardDatePeriodFiveMember2018-01-012018-12-310000353278nvo:AwardDatePeriodSevenMembernvo:SharesAllocatedtoIndividualEmployeesMember2020-01-012020-12-310000353278nvo:SharesAllocatedtoIndividualEmployeesMembernvo:AwardDatePeriodSixMember2019-01-012019-12-310000353278nvo:SharesAllocatedtoIndividualEmployeesMembernvo:AwardDatePeriodFiveMember2018-01-012018-12-310000353278nvo:AwardDatePeriodSixMembernvo:RestrictedStockUnitsToEmployeesMember2019-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMembernvo:AwardDatePeriodSevenMember2020-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMembernvo:AwardDatePeriodSixMember2019-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMembernvo:AwardDatePeriodFiveMember2018-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementGroupBelowSeniorManagementBoardMembernvo:AwardDatePeriodSevenMember2020-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementGroupBelowSeniorManagementBoardMembernvo:AwardDatePeriodSixMember2019-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementGroupBelowSeniorManagementBoardMembernvo:AwardDatePeriodFiveMember2018-12-310000353278nvo:AwardDatePeriodSevenMembernvo:SharesAllocatedtoIndividualEmployeesMember2020-12-310000353278nvo:SharesAllocatedtoIndividualEmployeesMembernvo:AwardDatePeriodSixMember2019-12-310000353278nvo:SharesAllocatedtoIndividualEmployeesMembernvo:AwardDatePeriodFiveMember2018-12-310000353278nvo:AwardDatePeriodSevenMembernvo:RestrictedStockUnitsToEmployeesMember2019-12-310000353278nvo:AwardDatePeriodSixMembernvo:RestrictedStockUnitsToEmployeesMember2018-12-310000353278nvo:AwardDatePeriodFiveMembernvo:RestrictedStockUnitsToEmployeesMember2017-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMembernvo:AwardDatePeriodSevenMember2019-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMembernvo:AwardDatePeriodSixMember2018-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMembernvo:AwardDatePeriodFiveMember2017-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementGroupBelowSeniorManagementBoardMembernvo:AwardDatePeriodSevenMember2019-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementGroupBelowSeniorManagementBoardMembernvo:AwardDatePeriodSixMember2018-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementGroupBelowSeniorManagementBoardMembernvo:AwardDatePeriodFiveMember2017-12-310000353278nvo:AwardDatePeriodSevenMembernvo:SharesAllocatedtoIndividualEmployeesMember2019-12-310000353278nvo:SharesAllocatedtoIndividualEmployeesMembernvo:AwardDatePeriodSixMember2018-12-310000353278nvo:SharesAllocatedtoIndividualEmployeesMembernvo:AwardDatePeriodFiveMember2017-12-310000353278nvo:AwardDatePeriodSevenMembernvo:RestrictedStockUnitsToEmployeesMember2020-01-012020-12-310000353278nvo:AwardDatePeriodFiveMembernvo:RestrictedStockUnitsToEmployeesMember2018-01-012018-12-310000353278nvo:AwardDatePeriodSevenMembernvo:RestrictedStockUnitsToEmployeesMember2020-12-310000353278nvo:AwardDatePeriodFiveMembernvo:RestrictedStockUnitsToEmployeesMember2018-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMembernvo:ChiefExecutiveOfficer1Member2020-01-012020-12-310000353278nvo:ExecutiveManagementMembernvo:LongTermShareBasedIncentiveProgrammeManagementBoardMember2020-01-012020-12-310000353278nvo:LongTermShareBasedIncentiveProgrammeManagementBoardMembernvo:SeniorVicePresidentsMember2020-01-012020-12-310000353278ifrs-full:ForeignCountriesMember2020-12-310000353278srt:ScenarioForecastMember2020-01-012024-12-310000353278srt:ScenarioForecastMember2021-01-012021-12-310000353278srt:ScenarioForecastMember2022-01-012022-12-310000353278srt:ScenarioForecastMember2023-01-012023-12-310000353278srt:ScenarioForecastMember2024-01-012024-12-310000353278srt:ScenarioForecastMember2020-01-012020-12-310000353278ifrs-full:ParentMembernvo:NovoHoldingsASMember2020-01-012020-12-310000353278ifrs-full:ParentMembernvo:NovoHoldingsASMember2019-01-012019-12-310000353278ifrs-full:ParentMembernvo:NovoHoldingsASMember2018-01-012018-12-310000353278nvo:NNITGroupMemberifrs-full:AssociatesMember2020-01-012020-12-310000353278nvo:NNITGroupMemberifrs-full:AssociatesMember2019-01-012019-12-310000353278nvo:NNITGroupMemberifrs-full:AssociatesMember2018-01-012018-12-310000353278ifrs-full:RelatedPartiesMembernvo:NovozymesGroupMember2020-01-012020-12-310000353278ifrs-full:RelatedPartiesMembernvo:NovozymesGroupMember2019-01-012019-12-310000353278ifrs-full:RelatedPartiesMembernvo:NovozymesGroupMember2018-01-012018-12-310000353278ifrs-full:RelatedPartiesMembernvo:ChurchillStatesideSolarFundXIVLLCMember2020-01-012020-12-310000353278ifrs-full:RelatedPartiesMembernvo:ChurchillStatesideSolarFundXIVLLCMember2019-01-012019-12-310000353278ifrs-full:RelatedPartiesMembernvo:ChurchillStatesideSolarFundXIVLLCMember2018-01-012018-12-310000353278ifrs-full:RelatedPartiesMembernvo:ChurchillStatesideSolarFundXIVLLCMember2020-12-310000353278ifrs-full:RelatedPartiesMembernvo:ChurchillStatesideSolarFundXIVLLCMember2019-12-310000353278ifrs-full:RelatedPartiesMembernvo:ChurchillStatesideSolarFundXIVLLCMember2018-12-310000353278ifrs-full:ParentMembernvo:BShareCapitalMembernvo:NovoHoldingsASMember2020-01-012020-12-310000353278srt:NorthAmericaMembernvo:NovoNordiskCanadaIncMember2020-01-012020-12-310000353278srt:NorthAmericaMembernvo:NovoNordiskIncMember2020-01-012020-12-310000353278nvo:NovoNordiskNorthAmericaOperationsASDenmarkMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaceuticalIndustriesLPMembersrt:NorthAmericaMember2020-01-012020-12-310000353278srt:NorthAmericaMembernvo:NovoNordiskPharmaIncMember2020-01-012020-12-310000353278nvo:NovoNordiskResearchCenterIndianapolisIncMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:NovoNordiskResearchCenterSeattleIncMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:NovoNordiskUSBioProductionIncMembersrt:NorthAmericaMember2020-01-012020-12-310000353278srt:NorthAmericaMembernvo:NovoNordiskUSCommercialHoldingsIncUnitedStatesMember2020-01-012020-12-310000353278srt:NorthAmericaMembernvo:NovoNordiskUSHoldingsIncMember2020-01-012020-12-310000353278nvo:CorvidiaTherapeuticsIncMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:EmisphereTechnologiesIncMembersrt:NorthAmericaMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaceuticalsASDenmarkMembernvo:InternationalMember2020-01-012020-12-310000353278nvo:InternationalMembernvo:NovoNordiskPharmaOperationsASMember2020-01-012020-12-310000353278nvo:NovoNordiskRegionAAMEOandLATAMASMembernvo:InternationalMember2020-01-012020-12-310000353278nvo:InternationalMembernvo:NovoNordiskRegionEuropeASMember2020-01-012020-12-310000353278nvo:JAPANANDKOREAMembernvo:NovoNordiskRegionJapanKoreaASMember2020-01-012020-12-310000353278nvo:RegionAfricaAsiaMiddleEastAndOceaniaMembernvo:AldaphSpAMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaGmbHMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:S.A.NovoNordiskPharmaN.V.Membersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmad.o.o.Membersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaEADMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskHrvatskad.o.o.Membersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordisks.r.o.Membersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskDenmarkASDenmarkMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmatechASMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskEgyptLLCMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskFarmaOYMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskFranceMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskProductionSASMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaGmbHGermanyMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskHellasEpe.Membersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskHungriaKft.Membersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskBiopharmLimitedIrelandMembersrt:EuropeMember2020-01-012020-12-310000353278srt:EuropeMembernvo:NovoNordiskLimitedIrelandMember2020-01-012020-12-310000353278nvo:NovoNordiskLtdIsraelMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskS.P.A.Membersrt:EuropeMember2020-01-012020-12-310000353278nvo:RegionAfricaAsiaMiddleEastAndOceaniaMembernvo:NovoNordiskKazakhstanLLPKazakhstanMember2020-01-012020-12-310000353278nvo:NovoNordiskKenyaLtd.Membernvo:RegionAfricaAsiaMiddleEastAndOceaniaMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaSARLMembernvo:RegionAfricaAsiaMiddleEastAndOceaniaMember2020-01-012020-12-310000353278nvo:UABNovoNordiskPharmaMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskFarmadooelMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaSASMembernvo:RegionAfricaAsiaMiddleEastAndOceaniaMember2020-01-012020-12-310000353278srt:EuropeMembernvo:NovoNordiskB.V.Member2020-01-012020-12-310000353278nvo:NovoNordiskPharmaLimitedNigeriaMembernvo:RegionAfricaAsiaMiddleEastAndOceaniaMember2020-01-012020-12-310000353278nvo:NovoNordiskNorwayASNorwayMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaceuticalServicesSp.z.o.o.Membersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaSpcooPolandMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskComrciodeProdutosFarmacuticosLda.Membersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskFarmaS.R.L.Membersrt:EuropeMember2020-01-012020-12-310000353278nvo:RegionAfricaAsiaMiddleEastAndOceaniaMembernvo:NovoNordiskLimitedLiabilityCompanyRussiaMember2020-01-012020-12-310000353278nvo:RegionAfricaAsiaMiddleEastAndOceaniaMembernvo:NovoNordiskProductionSupportLLCMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmad.o.o.BelgradeSerbiaMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskSlovakias.r.o.Membersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskd.o.o.SloveniaMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskPtyLimitedSouthAfricaMembernvo:RegionAfricaAsiaMiddleEastAndOceaniaMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaS.A.SpainMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskScandinaviaABSwedenMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskHealthCareAGSwitzerlandMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaAGSwitzerlandMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:RegionAfricaAsiaMiddleEastAndOceaniaMembernvo:NovoNordiskTunisieSARLMember2020-01-012020-12-310000353278nvo:RegionAfricaAsiaMiddleEastAndOceaniaMembernvo:NovoNordiskSaglikrnleriTic.Ltd.Sti.Member2020-01-012020-12-310000353278nvo:NovoNordiskUkraineLLCUkraineMembernvo:RegionAfricaAsiaMiddleEastAndOceaniaMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaGulfFZLLCMembernvo:RegionAfricaAsiaMiddleEastAndOceaniaMember2020-01-012020-12-310000353278nvo:NovoNordiskHoldingLimitedUnitedKingdomMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskLimitedUnitedKingdomMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:ZiyloLimitedUnitedKingdomMembersrt:EuropeMember2020-01-012020-12-310000353278nvo:NovoNordiskChinaPharmaceuticalsCo.Ltd.Membercountry:CN2020-01-012020-12-310000353278nvo:NovoNordiskRegionChinaASDenmarkMembercountry:CN2020-01-012020-12-310000353278nvo:BeijingNovoNordiskPharmaceuticalsScienceTechnologyCo.Ltd.Membercountry:CN2020-01-012020-12-310000353278country:CNnvo:NovoNordiskHongKongLimitedMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaTaiwanLtd.Membercountry:CN2020-01-012020-12-310000353278nvo:RestOfWorldMembernvo:NovoNordiskPharmaArgentinaS.A.Member2020-01-012020-12-310000353278nvo:NovoNordiskPharmaceuticalsPty.Ltd.Membernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaPrivateLimitedMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoNordiskProduoFarmacuticadoBrasilLtdaMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoNordiskFarmacuticadoBrasilLtdaMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoNordiskFarmacuticaLimitadaMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoNordiskColombiaSASMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoNordiskIndiaPrivateLimitedMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoNordiskServiceCentreIndiaPvt.LtdMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:PT.NovoNordiskIndonesiaMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoNordiskParsMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaLtdMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaMalaysiaSdnBhdMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaOperationsBusinessAreaSdnMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:RestOfWorldMembernvo:NovoNordiskMexicoS.A.deC.V.Member2020-01-012020-12-310000353278nvo:NovoNordiskPharmaceuticalsLtd.NewZealandMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:RestOfWorldMembernvo:NovoNordiskPharmaPrivateLimitedPakistanMember2020-01-012020-12-310000353278nvo:NovoNordiskPanamaS.A.Membernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoNordiskPeruS.A.C.Membernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaceuticalsPhilippinesInc.Membernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaSingaporePteLtd.Membernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoInvestmentPteLimitedMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaKoreaLtdMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoNordiskLankaPVTLtdSriLankaMembernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoNordiskPharmaThailandLtd.Membernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NovoNordiskVenezuelaCasadeRepresentacinC.A.Membernvo:RestOfWorldMember2020-01-012020-12-310000353278nvo:NNEASDenmarkMemberifrs-full:CountryOfDomicileMember2020-01-012020-12-310000353278ifrs-full:CountryOfDomicileMembernvo:NNITASDenmarkMember2020-01-012020-12-310000353278nvo:ChurchillStatesideSolarFundXIVLLCMembercountry:US2020-01-012020-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM 6-K
________________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

February 3, 2021

_________________________

NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
_________________________
Novo Allé
DK-2880 Bagsværd
Denmark
(Adress of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F x Form 40-F o


Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x


If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_______



Novo Nordisk Annual Report 2020



nvo-20201231_g1.jpg

Team Novo Nordisk, the world's first all-diabetes professional cycling team, are racing with 100 on their jersey to celebrate the 100-year anniversary of the discovery of insulin.
Novo Nordisk A/S - Novo All 1, 2880 Bagsværd, Denmark - CVR no. 24256790



Introducing Novo Nordisk / Strategic aspirations / Corporate governance / Consolidated statements / Additional informationNovo Nordisk Annual Report 2020 /
2

Contents

nvo-20201231_g2.jpg







Management review
Introducing Novo Nordisk
Letter from the Chair . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Letter from the CEO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Novo Nordisk at a glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Business model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Performance highlights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Strategic aspirations
Purpose and sustainability . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Innovation and therapeutic focus . . . . . . . . . . . . . . . . . . . . . . 20
Commercial execution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
Financials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Corporate governance
Risk management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Shares and capital structure . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Corporate governance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Governance practices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
Board of Directors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Executive Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45


Consolidated statements
Consolidated financial statements
Income statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Cash flow statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Balance sheet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
Equity statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
Notes to the consolidated financial statements . . . . . . . . . . 51
Consolidated ESG statement (supplementary information)
Statement of ESG performance . . . . . . . . . . . . . . . . . . . . . . . 81
Notes to the consolidated ESG statement . . . . . . . . . . . . . .82
Statements and Auditor's Reports
Statement by Board of Directors and
Executive Management. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
88
Independent Auditor's Reports . . . . . . . . . . . . . . . . . . . . . . . . 89
Independent Assurance Report on the ESG statement . . . 91
Additional information
More information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .92
Product overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93




Introducing Novo Nordisk / Strategic aspirations / Corporate governance / Consolidated statements / Additional information
Novo Nordisk Annual Report 2020 /
3


nvo-20201231_g3.jpg
Letter from the Chair
Rising to the
challenge









The devastating impact of COVID-19 on societies and economies in 2020 intensified existing challenges such as inequality and poverty. However, in times of crisis, businesses play a critical role in mobilising resources and providing solutions. Novo Nordisk has worked hard to respond to the challenges, helping people with serious chronic diseases while also supporting society on a broader scale.

Novo Nordisk’s highest priority in 2020 was to ensure the safety of our employees and the uninterrupted supply of our life-saving medicines for patients. We achieved this, while also supporting society's response to the pandemic, most notably in Denmark, where our headquarter presence meant we were able to assist the government in the rapid scale-up of coronavirus testing. At the same time, our scientists continued to make significant progress in discovering new therapies of the future, while our

global commercial organisation embraced an increasingly digital new reality.

The world has been through one of the most difficult years in recent human history. Despite the pandemic and the turbulent business environment, Novo Nordisk took important steps towards delivering on our purpose of driving change to defeat diabetes and other serious chronic diseases – a goal we are confident will translate into sustainable and profitable growth.



Introducing Novo Nordisk / Strategic aspirations / Corporate governance / Consolidated statements / Additional information
Novo Nordisk Annual Report 2020 /
4

This does not mean that the road ahead is going to be easy. The pandemic has exacted an immense economic, as well as human, cost on societies and it is inevitable that public finances will remain fragile for many years. Those fiscal constraints will put pressure on businesses that work closely with governments, including the pharmaceutical industry, and we will have to find new ways to ensure that our products are accessible to all those who need them.

Beyond COVID-19, two consistent priorities were high on the Board’s agenda in 2020, namely scientific innovation and sustainability – both of which are vital to ensure the future of the company. It is therefore satisfying to see a healthy product pipeline, including the pioneering science that we consider to be the biggest contribution we can make to society.

Our research is now more broadly focused as we look to deliver treatments within therapy areas adjacent to our core competencies. Specifically, this means looking beyond semaglutide, the GLP-1 molecule found in our new oral diabetes treatment Rybelsus® and the once-weekly injectable Ozempic®. We are exploring novel ways to treat a range of conditions beyond diabetes, including cardiovascular disease – the world’s leading cause of death1 – obesity and most recently also as a potential treatment for Alzheimer’s disease. In tandem with this push into new areas, we are also establishing more external alliances and partnerships to complement our in-house expertise.
nvo-20201231_g4.jpg
Employees from the Novo Nordisk research department volunteered to contribute to the fight against COVID-19 and, together with staff from the Danish health service, they helped to increase the testing capacity in Denmark.
"Above all, 2020 underscored the need for strong corporate values and a shared sense of purpose. We are fortunate that both are well-established across our organisation, empowering our employees to keep delivering for both patients and investors, despite the unprecedented disruptions caused by COVID-19."




1.WHO, The top 10 causes of death (2020)
It is increasingly clear that society expects more from businesses as the world grapples with climate change and environmental degradation, as well as the need for greater equity in healthcare. Indeed, the pandemic has turbocharged many of these issues, with an effective alliance emerging between young people and investors that is prompting companies to pay far more attention to sustainability.

At Novo Nordisk, we have been focused on sustainability for many years – but we are determined to continue to raise our game. In the past year we launched a new social responsibility strategy, Defeat Diabetes, and initiated programmes within renewable power and recycling as part of our Circular for Zero environmental strategy.
Above all, 2020 underscored the need for strong corporate values and a shared sense of purpose. We are fortunate that both are well-established across our organisation, empowering our employees to keep delivering for both patients and investors, despite the unprecedented disruptions caused by COVID-19.


On behalf of the Board of Directors I would like to offer my thanks to all Novo Nordisk’s employees for their hard work and commitment during the exceptional challenges of 2020; to Lars Fruergaard Jørgensen and his team for leading the company through a turbulent year in such a thoughtful and positive manner; and to our shareholders for their continued support.


Helge Lund
Chair of the Board of Directors



Introducing Novo Nordisk / Strategic aspirations / Corporate governance / Consolidated statements / Additional information
Novo Nordisk Annual Report 2020 /
5


Letter from the CEO
The power of purpose






The COVID-19 pandemic has taken a terrible toll around the world – but the pain has not been shared equally. People with underlying conditions have been hit disproportionately hard by the virus, a fact that makes Novo Nordisk’s purpose of driving change to defeat diabetes and other serious chronic diseases more meaningful than ever.

Today, one in 11 people in the world has diabetes and if action is not taken to bend the curve, that figure is projected to rise to one in nine by 20451. The risk posed by COVID-19 to people living with diabetes and obesity is a clear wake-up call: we must continue to do more to tackle these diseases or risk vast future damage to millions of lives, as well as to broader societies and economies.

We measure our contribution to the fight against diabetes and other serious chronic diseases in our strategic aspirations for 2025. Appropriately, after a year as unparalleled as 2020, and as the world acknowledges the hundredth anniversary of the















discovery of insulin, the first of these is 'Purpose and sustainability'. Over the past year we have stepped up our commitment to our purpose by launching a new Defeat Diabetes social responsibility strategy. This sets out our ambition to accelerate the prevention of type 2 diabetes, provide access to affordable care for vulnerable patients in every country and innovate to improve lives.

Beyond defeating serious chronic diseases, we also aspire to have zero environmental impact.In 2020, we took an important step by achieving our target of using 100% renewable power across global production – a key milestone on the road to our target of zero CO2 emissions from all operations and transport by 2030.






1. IDF Diabetes Atlas, 9th edition, 2019




nvo-20201231_g5.jpg




Introducing Novo Nordisk / Strategic aspirations / Corporate governance / Consolidated statements / Additional information
Novo Nordisk Annual Report 2020 /
6

We now also ask that by the end of the decade, our direct suppliers use only renewable power when supplying us. It has been great to see some of our largest suppliers step up and meet this target already.

Despite this encouraging progress, we can only fulfil our purpose and be respected for adding value to society if we deliver on our core contribution of scientific innovation. Thanks to a strategy of targeted investment, our scientists are currently pursuing higher levels of innovation across more therapy areas than at any point in the company’s history. Consequently, I believe we are now well-positioned for success in the short, medium and long term.

Within diabetes, we are further raising the innovation bar with the roll-out of the world’s first once-daily GLP-1 tablet, Rybelsus®, while at the same time working on novel insulins, 100 years after the discovery of the molecule. Our Research & Development (R&D) colleagues are also pursuing greater weight loss in obesity, and in 2020 they demonstrated the potential of semaglutide 2.4 mg in the STEP phase 3 clinical trial programme.

Crucially, we also broadened our technology platforms and expanded our research into adjacent disease areas in 2020 including cardiovascular disease, non-alcoholic steatohepatitis (NASH) and Alzheimer’s disease – areas of huge unmet medical need and a great burden for patients, families and society alike.

Our continued focus on external innovation led to the significant acquisitions of Corvidia Therapeutics and Emisphere Technologies, strengthening our positions in cutting-edge
areas of cardiovascular medicine and drug delivery respectively.

nvo-20201231_g6.jpg


Commercially, 2020 was a challenging year as lockdowns reduced the time doctors spent with their patients, leading to fewer initiations of new treatments. Despite this, we expanded our leadership position in the diabetes market in terms of value, keeping us on track to reach a share of more than one third by 2025. Diabetes sales were driven by sales of GLP-1 products (Victoza®, Ozempic® and Rybelsus®), which offset mixed market conditions for insulins. We continued to help more people living with obesity, while making progress with our ambition to secure sustained growth within our Biopharm division thanks to strong demand for our growth hormone and new haemophilia products.

I believe that our ability to meet the needs of our millions of patients during the pandemic in 2020 comes as a consequence of our crystal-clear purpose and long-established company values. We are far from done and have many more millions of patients for whom treatment is not accessible
today. So now is the time to continue to invest in our people and in our organisation, creating an inclusive, diverse and safe working environment in which colleagues have equal opportunities to thrive and fulfil their potential.

Looking to the future, I am confident that our clear corporate strategy will make us a valued partner to society as the world continues on the long road to recovery from the pandemic.

In closing, I would like to thank my colleagues around the world for their agility and commitment during this most challenging of years. Special thanks must go to our partners and collaborators, without whom we could not succeed. A sincere thank you goes to our Board of Directors for their continued support and constructive challenging of the organisation. Finally, I would like to send a thank you to our shareholders for their continuous support.


Lars Fruergaard Jørgensen
President & Chief Executive Officer


“Over the past year we have stepped up our commitment to our purpose by launching a new Defeat Diabetes social responsibility strategy. This sets out our ambition to accelerate the prevention of type 2 diabetes, provide access to affordable care for vulnerable patients in every country and innovate to improve lives."






Introducing Novo Nordisk / Strategic aspirations / Corporate governance / Consolidated statements / Additional information
Novo Nordisk Annual Report 2020 /
7

Novo Nordisk at a glance
Novo Nordisk is a global healthcare company, headquartered in Denmark. Our key contribution is to discover and develop innovative bio- logical medicines and make them accessible to patients throughout the world. We aim to lead in all disease areas in which we are active.Our corporate strategy has four distinct focus areas in which we operate. It is built on our purpose, the Novo Nordisk Way and our ambition to be a sustainable business.We aim to strengthen our leadership and treatment options in Diabetes and Obesity care, secure leading positions within Biopharm and establish a strong presence in other serious chronic diseases such as NASH, cardiovascular disease and Alzheimer’s disease. Succeeding in this will drive sustainable growth for Novo Nordisk.
126,946
nvo-20201231_g7.jpg
463
DKK million in net sales
million people live with diabetes1
54,126650
DKK million in operating profit
million people live with obesity2
28,565450
DKK million in free cash flow
thousand people live with haemophilia3
45,323
employees worldwide
169
countries with marketed products

80
countries with affiliates
51. IDF Diabetes Atlas, 9th edition, 2019
2. WHO, Obesity and overweight, fact sheet, 2020
3. World Federation of Hemophilia, Annual Survey, 2018
countries with R&D facilities



Introducing Novo Nordisk / Strategic aspirations / Corporate governance / Consolidated statements / Additional information
Novo Nordisk Annual Report 2020 /
8


Our business model


Our business is built around our purpose: Driving change to defeat diabetes and other serious chronic diseases. Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world.

We strive to be a sustainable business, creating value to society and to our future business. We do business in a financially, environmentally and socially responsible manner and we do this the Novo Nordisk Way. By succeeding in this, we will create long-term value to patients, employees, partners, shareholders and society.
nvo-20201231_g8.jpg
Resources
Resources going into our business model at different stages:
Insights from healthcare experts, patients and partners
Expertise from public and private institutions
Diverse talent
Raw materials
Financial resources


Value
Value created from our business:
32.8 million people using our Diabetes care products
43,500 patients participating in our clinical trials
45,323 employees, of whom 5,446 were new hires in 2020
60,000 direct suppliers
26,376 DKK million total tax contribution
36,976 DKK million to shareholders as dividends and share repurchases




Introducing Novo Nordisk / Strategic aspirations / Corporate governance / Consolidated statements / Additional information
Novo Nordisk Annual Report 2020 /
9


Performance highlights
Strategic aspirations 2025



To reflect the broad aspects of Novo Nordisk across therapy areas and geographies, Novo Nordisk introduced in 2019 a comprehensive approach describing the future growth aspirations of the company under the headline Strategic Aspirations 2025. The strategic aspirations are objectives that Novo Nordisk intends to work towards and are not a projection of Novo Nordisk's financial outlook or expected growth.










1.CER: Constant Exchange Rate
2.IO: International Operations
3.NAO: North America Operations
nvo-20201231_g9.jpgPurpose and sustainability
nvo-20201231_g10.jpgInnovation and therapeutic focus
2025 strategic aspirations2020 highlights2025 strategic aspirations2020 highlights
Being respected for adding value to society
Progress towards zero environmental impact
Ensure distinct core capabilities and evolve culture
Adding value to society:
Launch of new social responsibility strategy, Defeat Diabetes
Expansion of US affordability offerings
Societal contributions during COVID-19
Lowered ceiling price of human insulin in 76 countries
Environment:
100% renewable power across all production sites
Launch of supplier target aiming at 100% renewable power by 2030
Ensure distinct capabilities and evolve culture
Progress on diversity and inclusion agenda, acceleration of agility mindset and digitalisation capabilities
Further raise the innovation bar for diabetes treatment
Develop a leading portfolio of superior treatment solutions for obesity
Strengthen and progress the Biopharm pipeline
Establish presence in other serious chronic diseases focusing on cardiovascular disease (CVD), NASH and chronic kidney disease (CKD)
Diabetes:
Semaglutide 2.0 mg phase 3b trial successfully completed
Once-weekly insulin icodec phase 3 trial programme initiated
Rybelsus® approved in the EU, the UK and Japan
Obesity:
Applications for semaglutide 2.4 mg submitted to FDA and EMA
AM833 + semaglutide 2.4 mg phase 1 trial successfully completed
Biopharm:
Mim8 phase 1/2 trial initiated
Concizumab phase 3 trial reinitiated
Other serious chronic disease:
Successful completion of phase 2 trials for ziltivekimab and semaglutide in NASH
nvo-20201231_g11.jpgCommercial execution
nvo-20201231_g12.jpgFinancials
2025 strategic aspirations2020 highlights2025 strategic aspirations2020 highlights
Strengthen diabetes leadership – aim at global value market share of more than 1/3
Strengthen obesity leadership and double 2019 reported sales
Secure a sustained growth outlook for Biopharm
Diabetes sales increased by 8% at CER1
Value market share leadership expanded by 0.7 percentage points to 29.3%
Obesity sales increased by 3% at CER to DKK 5.6 billion
Biopharm sales increased by 1% at CER
Deliver solid sales and operating profit growth:
Deliver 6–10% sales growth in IO2
Transform 70% of sales in the US (from 2015 to 2022)
Drive operational efficiencies across the value chain to enable investments in future growth assets
Deliver free cash flow to enable attractive capital allocation to shareholders
Operating profit increased by 7%
at CER to DKK 54.1 billion
Sales increased by 7% at CER, to DKK 126.9 billion
10% sales growth at CER in IO
3% sales growth at CER in NAO3, with 48% of US sales transformed to products launched since 2015
Free cash flow of DKK 28.6 billion and DKK 37 billion returned to shareholders






Introducing Novo Nordisk / Strategic aspirations / Corporate governance / Consolidated statements / Additional information
Novo Nordisk Annual Report 2020 /
10

Performance highlights
Financial highlights


DKK million201620172018201920202019–2020
nvo-20201231_g13.jpg
Financial performanceChange
Net sales111,780111,696111,831122,021126,946%
Sales growth as reported3.6 %(0.1 %)0.1 %9.1 %4.0 %
Sales growth in constant exchange rates (CER)1
5.5 %2.3 %4.6 %5.6 %6.7 %
Operating profit48,43248,96747,24852,48354,126%
Operating profit growth as reported(2.0 %)1.1 %(3.5 %)11.1 %3.1 %
Operating profit growth in constant exchange rates (CER)1
0,2%4.8 %2.8 %5.6 %6.8 %
Depreciation, amortisation and impairment losses3,1933,1823,9255,6615,753
Net financials(634)(287)367(3,930)(996)
Profit before income taxes47,79848,68047,61548,55353,130%
Effective tax rate2
20.7 %21.7 %18.9 %19.8 %20.7 %
Net profit 37,92538,13038,62838,95142,138%
Purchase of intangible assets2
1,1991,0222,7742,29916,256607 %
Purchase of property, plant and equipment2
7,0687,6269,6368,9325,825(35 %)
Free cash flow1
39,99132,58832,53634,45128,565(17 %)
Total assets97,539102,355110,769125,612144,92215 %
Equity 45,26949,81551,83957,59363,32510 %
Financial ratios
Gross margin2
84.6 %84.2 %84.2 %83.5 %83.5 %
nvo-20201231_g14.jpg
Sales and distribution costs in percentage of sales25.4 %25.4 %26.3 %26.1 %25.9 %
Research and development costs in percentage of sales13.0 %12.5 %13.2 %11.7 %12.2 %
Operating margin2
43.3 %43.8 %42.2 %43.0 %42.6 %
Net profit margin2
33.9 %34.1 %34.5 %31.9 %33.2 %
Cash to earnings1
105.4 %85.5 %84.2 %88.4 %67.8 %
Operating profit after tax to net operating assets1
150,2%143,2%116,7%98,0%82.8 %
Dividend payout ratio2
50.2 %50.4 %50.6 %50.5 %50.0 %
Share performance
Basic earnings per share/ADR in DKK2
14.9915.4215.9616.4118.0510 %
Diluted earnings per share/ADR in DKK2
14.9615.3915.9316.3818.0110 %
Total number of shares (million), 31 December2,5502,5002,4502,4002,350(2 %)
Dividend per share in DKK7.607.858.158.359.10
3
%
Total dividend (DKK million)19,04819,20619,54719,65121,066
3
%
Share repurchases (DKK million)15,05716,84515,56715,33416,85510 %
Closing share price (DKK)25533529838742710 %
1. See 'Non-IFRS financial measures' 2. See 'Financial definitions'. 3. Total dividend for the year including interim dividend of DKK 3.25 per share, corresponding to DKK 7,570 million, which was paid in August 2020. The remaining DKK 5.85 per share, corresponding to DKK 13,496 million, will be paid subject to approval at the Annual General Meeting.






Introducing Novo Nordisk / Strategic aspirations - Purpose and sustainability / Corporate governance / Consolidated statements / Additional information
Novo Nordisk Annual Report 2020 /
11


Purpose and sustainability
Adding value to society
and to our future
business





Demands on companies are changing fast as the world is faced with extraordinary challenges. Threats like the COVID-19 pandemic and climate change mean that 'business as usual' is no longer an option. The stakes are high and we are determined to be a sustainable business by adding value to society and to our future business.
Responding to COVID-19
During 2020, COVID-19 led to a cascade of critical needs around the world and we used our expertise, resources and global reach to contribute to the response. Our highest priority was to ensure the safety of our employees and the uninterrupted supply of life-saving medicines for our patients. In addition, we focused our resources on donations towards global relief efforts and activated our research and development organisation to perform COVID-19 testing following a request for support from the Danish government.

Leading a sustainable business
Our purpose is to drive change to defeat diabetes and other serious chronic diseases. To maximise our positive impact, we must offer solutions beyond providing medicines to help tackle the global societal challenges of growth in non-communicable diseases, lack of access to affordable care and the impacts of climate change.

We are committed to being a sustainable business. To us, this means that we add value to society and to our future business. To achieve this ambition, we do business in a financially, environmentally and socially responsible way, as reflected in our Articles of Association and the Novo Nordisk Way. This approach is integrated into every aspect of our decision-making, in strategies and actions, always keeping in mind what is best in the long term for the patients we serve, our shareholders, our employees, the communities in which we are present and the global society we are part of.
nvo-20201231_g15.jpg
2025 strategic aspiration
 nvo-20201231_g16.jpgPurpose and sustainability

Being respected for adding value to society
Progress towards zero environmental impact
Ensure distinct core capabilities and evolve culture
The rapid outbreak of COVID-19 during 2020 put the potential vulnerability of people living with diseases, including diabetes and obesity, firmly in the spotlight. At the same time, climate change remains an urgent challenge. These challenges call for corporations to step up and take a leading role in delivering and adopting solutions.

In 2020 we addressed these challenges by increasing access to our medicines across the world, pursuing zero environmental impact, and taking steps towards creating a more sustainable and inclusive workplace.
With that, we lead towards our strategic aspirations within purpose and sustainability.

This is what ESG – Environmental, Social and Governance – means to us.

Read more about ESG in the following sections
and in the consolidated ESG statement.




Introducing Novo Nordisk / Strategic aspirations - Purpose and sustainability / Corporate governance / Consolidated statements / Additional information
Novo Nordisk Annual Report 2020 /
12


Purpose and sustainability
Our environmental responsibility



Each year, billions of Novo Nordisk tablets, vials and injection pens are distributed to patients and demand for them is growing.
This puts us in the front line of some of the most challenging environmental issues including climate change, water and resource scarcity, pollution and plastic waste. Our ambition is bold and simple: to have zero environmental impact.


To get there, we are adopting a circular mindset, designing products that can be re-used or recycled, reshaping our business practice to minimise consumption and eliminate waste, and working with suppliers who share our ambition. We call our environmental strategy Circular for Zero and we measure our progress based on use of resources, emissions and waste. The Circular for Zero strategy incorporates our entire value chain and is based on three pillars: circular supply, circular company and circular products.
Circular supply
As part of our ambition to switch to circular sourcing and procurement, we collaborate with suppliers to encourage them to shift to sustainably sourced materials, thus reducing our environmental impact. In 2020 we set an ambitious target that all our direct suppliers should source 100% renewable power by 2030 when supplying us. To achieve this, we will work with our suppliers to help them in this transition to renewable power. Successful conversion among our 60,000 suppliers would result in around 300,000 tonnes of CO2 being eliminated from our direct suppliers each year.

Circular company
We work to reduce our environmental impact across all areas of our operations and transportation. In 2020, total CO2 emissions across our operations and transportation were 170,000 tonnes of CO2, representing a 44% decrease from 2019, due primarily to the implementation of renewable energy projects and impacts on travel from COVID-19.

CO2 emissions from operations includes all production facilities, global office buildings and laboratories. In 2020, CO2 emissions from production were 37,000 tonnes CO2, a reduction of 57% versus 2019, primarily due to the implementation of various renewable energy initiatives. These projects include implementation of renewable heat and steam in Kalundborg, wind power in France, Algeria and Russia, and solar power in the USA. CO2 emissions from office buildings and laboratories were 8,000 tonnes CO2, a decrease of 38% versus 2019, due primarily to energy-saving projects and COVID-19 shut-downs.
nvo-20201231_g17.jpg
nvo-20201231_g18.jpg

Due to COVID-19, CO2 emissions from business flights were reduced to 19,000 tonnes CO2, a reduction of 71% compared with 2019. During 2021, we will focus on ensuring that emissions from business travel are minimised through the promotion of virtual collaboration with both colleagues and stakeholders. CO2 emissions from our company cars in 2020 were 45,000 tonnes CO2, 27% lower than in 2019, primarily due to fewer in-person meetings and less travel as a result of COVID-19. Novo Nordisk is a member of EV100 and has committed to transitioning to 100% electric company cars by 2030. In 2020, CO2 emissions from product distribution were 61,000 tonnes CO2, a decrease of 24% compared with 2019, due to optimisation projects to move products shipped from air to sea freight.

At the beginning of the year, we achieved our ambition of sourcing 100% renewable power in our global production when a new solar facility went online powering our entire US operations. In the process, we became the first pharmaceutical company in the renewable power initiative, RE100, to do this.



Introducing Novo Nordisk / Strategic aspirations - Purpose and sustainability / Corporate governance / Consolidated statements / Additional information
Novo Nordisk Annual Report 2020 /
13


nvo-20201231_g19.jpg
In 2020, the energy consumption for our operations was 3,191,000 GJ, an increase of 7% compared with 2019, primarily due to a new production site in North Carolina. Energy-saving projects implemented in 2020 within production sites are expected to result in annual savings of 94,000 GJ.

Water consumption at production sites was
3,368,000 cubic meters, an increase of 7% compared with 2019 due to the new production site in North Carolina. Four production sites including China and Brazil are in areas subject to water stress or high seasonal variations. These sites accounted for 11% of the total water consumption in 2020, and water consumption at these sites decreased by 15% in 2020, despite adding new production sites. We will continue to focus on reducing water consumption across these sites.

We are committed to reducing waste and have a target of sending zero production waste to landfill by 2030. In 2020, production sites had a total of 141,000 tonnes of waste, an increase of 14% compared with 2019. This increase was due to increased production in Kalundborg.

93% of waste arising from our production was recycled, converted to biogas or incinerated in waste-to-energy plants. During 2020 less than 1% (1,000 tonnes) of our waste was sent to landfill.
Circular products
We are working to ensure existing and new products are fit for circularity and have developed a circular design guideline within R&D to reduce the environmental footprint of our devices.

As part of Circular for Zero, we are seeking to address the end-of-life challenges associated with many of our medical devices. In late 2020, we initiated a pilot take-back scheme for medical devices in Denmark with the aim of scaling globally in the future. Through recycling our production waste, we have been able to successfully recycle insulin pens, providing materials for the manufacture of lamps and office furniture. We are pursuing greater re-use and recycling of our devices and aspire to achieve this in coming years.


“The Danish Association of Pharmacies is very excited to be part of this important take-back project aiming to reduce the environmental impact from used insulin pens, which consist of valuable materials suitable for recycling. By recycling we avoid the negative climate impact from burning the material as normal waste.”

Birthe Søndergaard, Danish Association of Pharmacies


Read more about our environmental performance in the consolidated ESG statement in this report and on novonordisk.com.
nvo-20201231_g20.jpg




Introducing Novo Nordisk / Strategic aspirations - Purpose and sustainability